Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Histiocytosis Clinical Presentation

  • Author: Cameron K Tebbi, MD; Chief Editor: Robert J Arceci, MD, PhD  more...
 
Updated: Jun 15, 2016
 

History

LCH can be localized and manifest as pain or may even be asymptomatic, as in isolated bone lesions. LCH can also involve multiple organs and systems, with clinically significant symptoms and consequences.[54] The clinical manifestations depend on the organs and systems involved as well as their level of involvement (see Physical).

Next

Classification

Classification of diseases involving histiocytic and dendritic cells is difficult, and classification systems must include a broad range of diseases. Therefore, most systems have been incomplete. The location of lesions and the extent of the disease substantially affect the course of the disease and the patient's prognosis. Thus, decisions regarding treatment are usually based on the extent of the disease and evidence of critical organ (risk organ) dysfunction (ie, lung, liver, spleen, bone marrow).

Classification of the World Health Organization

The classification of histiocytic disorders the World Health Organization (WHO) has proposed is as follows:[55]

  • Class I - Langerhans cell histiocytosis
  • Class II
    • Histiocytosis of mononuclear phagocytes other than Langerhans cells
    • Familial and reactive hemophagocytic lymphohistiocytosis (HLH)
    • Sinus histiocytosis with massive lymphadenopathy (SHML), Rosai-Dorfman disease
    • Juvenile xanthogranuloma (JXG)
    • Reticulohistiocytoma
  • Class III
    • Malignant histiocytic disorders
    • Acute monocytic leukemia (FAB M5)
    • Malignant histiocytosis
    • True histiocytic lymphoma

The WHO classification of neoplastic disorders of histiocytes and dendritic cells is as follows:

  • Macrophage or histiocyte related
    • Histiocytic sarcoma, mainly localized
    • Generalized malignant histiocytosis (may be related to acute monocytic leukemia)
  • Dendritic-cell related
    • 2A - Localized or generalized Langerhans cell histiocytosis
    • 2B - Langerhans cell sarcoma
    • 2C - Interdigitating dendritic cell sarcoma
    • 2D - Follicular dendritic cell sarcoma or tumor

Classification of the Histiocyte Society

The working classification of histiocytosis syndromes from the Histiocyte Society is as follows:

  • Dendritic-cell related
    • Langerhans cell histiocytosis
    • Xanthogranuloma
    • Erdheim-Chester disease
  • Macrophage related
    • HLH (genetic or sporadic)
    • SHML
  • Malignant disorders
    • Monocyte related, monocytic leukemia
    • Dendritic-cell related
    • Localized or macrophage related
    • Disseminated (malignant histiocytosis)

The following, adapted from the Writing Group of the Histiocyte Society, describes confidence levels for the diagnosis of class I Langerhans cell histiocytosis:[5]

  • Presumptive diagnosis - Light morphologic characteristics
  • Designated diagnosis - Light morphologic features plus 2 or more supplemental positive stains for the following:
    • Adenosinetriphosphatase
    • S-100 protein
    • Alpha-D-mannosidase
    • Peanut lectin
  • Definitive diagnosis - Light morphologic characteristics plus Birbeck granules in the lesional cell on electron microscopy and/or positive staining for CD1a antigen (T6) on the lesional cell

Previous and other classifications

Langerhans cell histiocytosis formerly was divided into 3 disease categories: eosinophilic granuloma, Hand-Schüller-Christian disease, and Letterer-Siwe (or Abt-Letterer-Siwe) disease, depending on the severity and extent of involvement. This classification and its related risk groups no longer are used. Systems based on these categories were meant to reflect the extent of involvement and its relationship to the patient's prognosis.[1, 56]

Some classifications, such as that of the 1987 Histiocyte Society classification schema, simply divide histiocytic disorders into class I Langerhans cell disease, class II non-Langerhans cell histiocytic disease without features of malignant disorders, and class III malignant histiocytic disorders.

A clinical-grouping system for Langerhans cell histiocytosis based on age, extent of the disease, and organ dysfunction, as once constructed,[57] can provide a means to compare patient data and prognoses. Various categories, such as limited and extensive multiorgan involvement, have also been proposed.

The Histiocyte Society developed a classification based on risk groups that arose from the first and second international (Langerhans cell histiocytosis I and II, respectively) trials of chemotherapy.[58] At-risk organs and systems identified in those trials included the liver, lung, spleen, and hematopoietic system. This risk classification is used in the treatment protocol of the third international study for Langerhans cell histiocytosis (LCH III).

Patients are stratified into 3 groups: (1) patients with multisystem disease associated with risk organ dysfunction (2) patients with multisystem involvement but without risk organ dysfunction, and (3) those with single-system multifocal bone disease or localized involvement of special sites (intraspinal extension or involvement of the paranasal, parameningeal, periorbital, or mastoid region).

In the trial, at-risk patients were randomly assigned to 1 of 2 treatment arms. Low-risk patients receive standard therapy for 6-12 months, and those with multifocal bone or special-site involvement receive the standard therapy for 6 months.

Previous
Next

Other Histiocytoses

Although this article focuses mainly on Langerhans cell histiocytosis, other histiocytoses include those listed below.

Dendritic-cell disorders

Multiple yellow-to-pink cutaneous nodules, which usually appear in the head and neck region, clinically characterize JXG. The nodules are often 0.5-1 cm in diameter, but a macronodular variant with lesions that measure several centimeters can also be seen. Lesions have been observed in the deep soft tissues or organs.[59, 60, 61] The condition usually presents at birth but can be observed during infancy. Similar lesions may be seen in adults.

In histologic evaluation, the lesions are well circumscribed and consist of an accumulation of histiocytic cells with giant cells and spindle cells. Immunohistochemical studies usually reveal positivity for factor XIIIa, fascin CD68, and peanut agglutinin lectin. Results for S-100 protein is often, but not exclusively, negative.

The course of JXG is usually marked by spontaneous resolution of the lesion. Systemic forms of JXG that involve the CNS can be devastating. Although no treatment is usually necessary, chemotherapy may be required to manage systemic forms of the disease.

Histiocytic disorders

Sinus hyperplasia

This disorder is a generally benign condition observed in lymph nodes, draining extremities, mesenteric regions, sites of malignant disorders, or foreign bodies. Erythrophagocytosis may be present in the involved lymph nodes. Sinuses are dilated and contain histiocytes. This is not a true histiocytic disorder but rather a normal lymph node response to draining antigen.

Sinus histiocytosis with massive lymphadenopathy (SHML)

Also called Rosai-Dorfman disease,[62, 63] this is a usually persistent, massive enlargement of the nodes by proliferation and accumulation of histiocytes that are characterized by emperipolesis.[64] The disease is rarely familial.[64, 65, 66, 67]

SHML is seen after bone marrow transplant for acute lymphoblastic leukemia, after or concurrent with diagnosis of lymphoma, herpes virus 6 (HHV6), and EBV infections.[65, 66, 67]

Although the disease is rarely familial,[64] a rare familial variation, termed Faisalabad histiocytosis, has been described in 2 families. These individuals have multiple congenital abnormalities including fractures, short stature, hearing impairment, joint contractures, and massive enlarged lymph nodes resembling Rosai-Dorfman disease. The disorder appears to be transmitted as an autosomal recessive syndrome.[68]

SHML cells are positive for CD68, CD163, α-antichymotrypsin, α-antitrypsin, Fascin and HAM-56. SHML cells express moderate IL6 cytokine.

The male-to-female ratio is about 4:3, with a higher prevalence in blacks than in whites. Systemic symptoms, such as fever, weight loss, malaise, joint pain, and night sweats, may be present. Cervical lymph nodes are most characteristically involved, but other areas, including extranodal regions, can be affected. These disorders can manifest with only rash or bone involvement.[62, 64, 69]

Immunologic abnormalities can be observed,[70] including leukocytosis; mild normochromic, normocytic, or microcytic anemia; increased Ig levels; abnormal rheumatoid factor; and positive results for lupus erythematosus are also reported.

Death from SHML is known to occur.[70]

The disease is pathologically benign and has a high rate of spontaneous remission, but persistent cases requiring therapy have occurred.[64, 70, 71] In exceptional cases with obstructive complications, surgery, radiation therapy, and chemotherapy have been used to treat the disease.[64]

Primary hemophagic lymphohistiocytosis (HLH)

Also known as familial erythrophagocytic lymphohistiocytosis (FHLH), this is a life-threatening disorder characterized by fever, enlargement of the liver (93%), spleen (94%), rash (30%),[72] and cytopenia.[73] The prevalence of FHLH is estimated to be in 0.12-1 in 100,000 live births, with equal male-to-female ratio. The disease is as a result of uncontrolled proliferation of activated lymphocytes and macrophages, as well as production of inflammatory cytokines.

This is a heterogenous autosomal recessive disorder, which is often seen in parental consanguinity. Five genetic subtypes (ie, FHL1, FHL2, FHL3, FHL 4, FHL 5) have been identified; molecular testing for FHL2 (PRF1), FHL3 (UNC13D), FHL4 (STX II), and FHL5 (STXBP2) are available.

The disease can manifest itself in utero, early in the neonatal period, during childhood, or, uncommonly, in adults. Manifestation of the disease includes neurological abnormalities, including irritability, stiffness of the neck, hypotoma or hypertoma, cranial nerve palsies, hemiaplasia, quadriplegia, loss of vision, ataxia, convulsions, and coma. Less common findings include rash and enlarged lymph nodes. Laboratory evaluation may disclose increased liver enzymes and finding hemophagocytosis in the bone marrow.

The disease is rapidly progressive and infections are common. Without appropriate treatment, the disease can be fatal. The median survival rate in untreated children is younger than 2 months.

Diagnosis of FHLH is based on the clinical findings and genetic testing. Because the disease may develop in utero, it can potentially be present at birth. Patients with nonsense mutation, including those with homozygosity for PRF, (p. Leu17 Argfs Ter 34) mutation and who are often of African descent, have tendency for onset of the disease at an earlier age. Also, generally, individuals with PRF1 mutations have an earlier onset of the disease than those with UNC13D mutation or patients for whom no mutations are identified.[74]

In general, those with missense mutations have later onset of their disease.[75] However, FHLH is usually diagnosed in childhood and rarely in adults as an acute disease. The symptoms include prolonged fever, cytopenia, hemoglobin level less than 9 g/L (93%), platelets less than 100 X 109/L (98%), neutrophils less than 1 X 109/L (75%), increased serum ferritin levels (93%), hypofibrinogenemia (76%), and CSF pleocytosis (52%).[72]

Enlargement of liver, spleen and lymph nodes occur occasionally and are accompanied by a rash. Neurological symptoms range from irritability, lethargy, hypotoma, hypertoma, ataxia, seizure disorder, increased intracranial pressure, hemi or quadriplegia, and cranial nerve involvement, including loss of vision. Liver dysfunction, including icterus and elevation of liver enzymes, is common;[76] hypertriglyceridemia and hypofibrinogenemia is seen as well.

These patients are prone to various infections. CSF may be positive for protein, increased mononuclear cells, or hemophagocytic cells. Bone marrow aspiration and biopsy typically reveals hemophagocytosis, which is the hallmark of this disease. This, however, may not be apparent early in the course. Genetic studies, as outlined above, are essential for definitive diagnosis. Cytolytic T lymphocyte (CTL)-mediated cytotoxicity can be impaired. Deficient natural killer cells (NK cell) activity is more often seen in individuals with PRF1 mutation than those without.

Immune dysregulation is one of the hallmarks of the disease, characterized by reduced or absent activity of the NK cells in most cases. CTL activity is also compromised.

Various mutations, deletions, or insertions that cause frameshift or missense mutation in perforin genes (PRF1 and PRF2),[77] MUNC 13-4, and syntaxin 11 have been reported. These findings often appear during the first year of life and almost always appear before age 17 years.

Primary HLH is linked to chromosomes 9 and 10. Genetic mutations in the perforin gene on chromosome 10 cause the disease in about 25-40% of genetically related patients.

Perforin gene mutation is reported in approximately one third of HLH cases. Mutation in MUNC13-4, a gene involved in cellular cytotoxicity that encodes for a protein that controls the fusion of the lytic granules to the plasma membranes, is associated with some FHLH cases (FHL3). The mutations can be scattered over different exons but, in most cases, fall within the protein functional domain.[78] A male predominance has been reported.[79, 80] In approximately 50-75% of patients, the disease is hereditary, with an autosomal recessive trait pattern. Parental consanguinity is common.[81] The disease is fatal if untreated.

Allogeneic bone marrow transplantation is the treatment of choice. However, the HLH-94 international protocol including VP16, steroids, and cyclosporine has excellent activity in achieving remission in most patients. When this protocol is combined with allogeneic bone marrow transplantation, more than 50% of patients can be cured.[82]

In patients with HLH, CNS disease is frequently seen. Almost 70% of patients have nonspecific abnormalities detectable with CT scan and MRI of the brain. The most common abnormalities include periventricular white matter involvement, with enlarged ventricular system, gray matter disorders, and brainstem and corpus callosum disease. Involvement of meninges is uncommon.[83]

Familial cases appear to be clustered in certain geographic areas of the world. PRF1 gene mutations are seen in whites, blacks, Japanese, Hispanics, and mixed races. Clusters of the disease have been reported in Asian, Turkish, Kurdish, Arabic, and Nordic populations. Associations with genes on other chromosomes have also been demonstrated. In a series of Japanese patients with HLH, 25% had mutations in the MUNC 13-4 gene (FHL2), a regulator of exocytosis in perforin-containing vesicles.[74] A small subgroup, dubbed FHL4, has been described in patients of Kurdish descent. A large consanguineous Kurdish kindred with 5 affected children had deletions in the syntaxin 11 gene on chromosome 6 (FLH4). Syntaxin 11 is a regulator of endocytosis.[84] This mutation is seen in approximately 21% of cases.[85] Further genetic mutations are under investigation.

Griscelli syndrome type II generally has the same symptoms as HLH because of associated immunodeficiency.

HLH reactive hemophagocytic syndrome

This is a reversible proliferation of histiocytes in response to viral, bacterial, fungal, and parasitic infections and autoimmune disorders, as well as to various cancers. This syndrome is most prevalent in individuals of Asian descent.[86] The disease may be a manifestation of impaired immune response to an infection or to secondary immunodeficiency, with many patients having defects in cellular cytotoxicity and immune deficiencies.[87]

Symptoms are often systemic and include fever and a viral-like illness. Patients frequently have a rash and an enlarged liver, spleen, and lymph nodes. Pancytopenia, increased liver enzyme levels, and an abnormal coagulation profile are common. Epstein-Barr virus is a common triggering organism.

Pathologically enlarged lymph nodes may have intact architecture with increased histiocytes in the sinusoids and paracortical areas. Histiocytes may exhibit platelet phagocytosis. Histiocytic hyperplasia may also be evident in the liver and spleen. The disease is usually self-limiting, but treatment with chemotherapy may be required when the disease is severe.

Instances of a combination of T-cell lymphoma with benign infiltration of histiocytes have been reported.[88, 89, 90] Upon histologic analysis, the process involves various types of malignant lymphomas, which are often of T-cell origin. Production of cytokines by lymphoma cells is suspected to cause phagocytosis. Upregulation of the TNF-alpha gene by Epstein-Barr virus and activation of macrophages by T cells infected with this virus, with interferon (INF) and other cytokine production, have been found.[91] Occurrence of LCH with various leukemias and solid tumors has also been reported.[92]

Lymphoma-associated hemophagocytic syndrome (LAHS) is a major subtype of the adult onset secondary HLH. This disorder has often lacks mass formation and delayed enlargement of the lymph nodes. The ratio of serum soluble interleukin-2 receptor to ferritin has been shown to be useful as a marker in diagnosis of LAHS.[93]

In some disorders, such as Kikuchi-Fujimoto disease (KFD) (histiocytic necrotizing lymphadenitis), which is a self-limiting disorder that affects cervical lymph nodes; hemophagocytic lymphohistiocytosis is seen.[94, 95]

Malignant T cells that express T-cell receptor gamma/delta have been found in adult and (rare) pediatric patients with fever and hepatosplenomegaly. The red pulp of spleen and sinusoids of the liver contain large lymphoid cells with erythrophagocytosis.[96, 97, 98, 99]

Histiocytic necrotizing lymphadenitis

This is a disease of unknown etiology and is usually observed in adolescents and adults. A female predilection is reported. The disease occurs in the cervical region; however, other locations, multiple sites, and rare extranodal involvement are reported.

Constitutional symptoms, such as fever, weight loss, nausea, vomiting, myalgia, arthralgia, and upper respiratory infection, may be present.[100]

Upon histologic study, necrosis of the nodes is observed in the paracortical area and, to a lesser extent, in the cortical area, with fibrin deposits, karyorrhectic debris, and macrophage infiltration. Areas adjacent to the foci of necrosis exhibit a reactive immunoblastic proliferation.

Laboratory findings are not diagnostic. The hematologic changes are nonspecific. Antibodies to Yersinia enterocolitica have been reported. The disease spontaneously resolves and rarely recurs. Systemic lupus erythematosus has been reported.[100]

Almost 70% of all patients with HLH have CNS abnormalities that can be seen using CT scanning or MRI. These findings are often nonspecific.[83]

Using flow cytometry, CD107a expression can be diagnostic for MUNC 13-4 defect and can potentially discriminate between genetic subtypes of FHLH.[101]

Dendritic lymphadenitis is a benign condition in which draining lymph nodes react to a skin lesion with paracortical expansion, dendritic cell infiltrates, and various degrees of follicular hyperplasia. Melanin pigment may be present.

Interdigitating dendritic cell sarcoma, indeterminate cell neoplasm, and fibroblastic reticular cell neoplasm are rare and nearly always affect adults.

Congenital solitary histiocytoma is a variant of self-healing solitary lesion of Hashimoto-Pritzker histiocytosis. This rare entity is seen in otherwise normal infants in the form of a solitary 5-mm to 15-mm nodule or papule at birth. Pathologically the skin lesion consists of predominantly histiocytes with admixture of lymphocyte and eosinophiles. Protein S100 and CD1a are positive and Birbeck granules may be present. Skin is the only site of involvement. Other organs and systems are not affected. The lesion is self-healing, apparently with no incidence of recurrence. Regular follow-up physical examination has been recommended.[102]

Previous
Next

Physical

When the disease is focal, establishing the diagnosis of Langerhans cell histiocytosis depends on a high level of suspicion. When advanced multisystem involvement is observed, diagnosis is often easy. Adequate workup to determine the extent of the disease and possible complications is essential. Biopsy and pathologic evaluation are needed to establish the diagnosis.

  • Bone involvement is observed in 78% of patients with Langerhans cell histiocytosis and often includes the skull (49%), innominate bone (23%), femur (17%), orbit (11%), and/or ribs (8%). Lesions of other bones are less common. See the image below.
    Clinically detectable skull lesions in a child wit Clinically detectable skull lesions in a child with advanced Langerhans cell histiocytosis (LCH).
    See the list below:
    • Upon clinical evaluation, the lesions can be singular or multiple. Asymptomatic or painful involvement of vertebrae can occur and can result in collapse.
    • Long-bone involvement can induce fractures. The lesions sometime cause a clinically significant periosteal reaction. Extension to the adjacent tissues can produce symptoms that may be unrelated to the bone involvement. Likewise, extraosteal involvement can occur in virtually any anatomic location, causing severe symptoms.[103]
    • In patients with advanced Langerhans cell histiocytosis, lesions may be clinically detectable in the skull (see Imaging Studies and the image above).
    • Ocular and periorbital involvement have been reported.[104] Manifestation of the disease often includes periorbital edema. Imaging studies may reveal destructive osteolytic lesions. The disease is usually unilateral, but bilateral involvement can occur. Biopsy is needed for confirmation. Treatment often includes partial resection and chemotherapy.[105]
  • Purulent otitis media may occur and may be difficult to distinguish from infectious etiologies. Long-term sequelae, including deafness, are reported. Orbital involvement may cause proptosis. Involvement of the eyes in the form of uveitis and iris nodules are reported. [106]
  • Diabetes insipidus and delayed puberty are observed in as many as 50% of patients (usual range is 15-25%). [107, 108, 109, 110, 111] Hypothalamic disease may also result in growth-hormone deficiency and short stature. [110, 112]
  • Maxillary, mandibular, and gingival disease may cause loss of teeth, hemorrhagic gum, and mucosal ulceration and bleeding. [113] Erosion of the gingiva (see the image below) may give the appearance of premature eruption of the teeth in young children. [113, 114]
    Erosion of the gingiva that creates the appearance Erosion of the gingiva that creates the appearance of premature eruption of the teeth in a young child.
  • Cutaneous Langerhans cell histiocytosis is observed in as many as 50% of patients with Langerhans cell histiocytosis. [115, 116, 117, 118] Rash is a common presentation, and skin lesions may be the only evidence of the disease or may be part of systemic involvement (see the image below). Skin infiltrates have a predilection for the midline of the trunk and the peripheral and flexural areas of skin. Skin infiltrates can be maculoerythematous, petechial xanthomatous, nodular papular, or nodular in appearance. Bronzing of the skin can occur.
  • Scalp disease frequently presents as scaly, erythematous patches, which may become petechial and eroded with serous crust (see the image below). The lesions often are not pruritic, but tenderness and alopecia can occur. In infants, a nodular form of the disease marked by eruption of lesions that mimic varicella has been reported. [116, 117, 119] This variety of the disease may spontaneously remit; this feature led to the name self-healing Langerhans cell histiocytosis.
  • Pulmonary involvement is observed in 20-40% of patients and may result in respiratory symptoms, such as cough, tachypnea, dyspnea, and pneumothorax. A male predominance is observed. Pulmonary function test results may be abnormal. [120, 121] Diffuse cystic changes, nodular infiltrate, pleural effusion, and pneumothorax are known to occur. [122] Imaging studies may reveal cysts and micronodular infiltrates. Pulmonary function tests may reveal restrictive lung disease with decreased pulmonary volume. [120, 121]
  • GI bleeding may be the presenting sign of patients with GI involvement. Appropriate imaging studies, endoscopy, and biopsy may be helpful to confirm the diagnosis. Liver involvement is characterized by elevated transaminase levels and, less commonly, increased bilirubin levels. Marrow involvement or enlargement of the spleen may cause hematologic changes.
  • Lymph node enlargement is observed in approximately 30% of patients. In rare cases, the nodes are symptomatic. If the volume is massive, it may obstruct or damage the surrounding organs and tissues. [123, 124] Suppuration and chronic drainage may occur. Lymph node enlargement surrounding the respiratory tract may result in pulmonary-related symptoms, such as cough, dyspnea, or cyanosis. Involvement of the thymus is relatively uncommon but does occur. [125]
  • Infiltration of various areas of the brain gives rise to corresponding signs and symptoms, including cerebellar dysfunction and loss of coordination. [126] Disruption of hypothalamic and pituitary function is most common. This includes symptoms secondary to diabetes insipidus and, to a lesser extent, growth-hormone deficiency and hypopituitarism. [112, 126, 127] Other symptoms, such as seizures and those related to increased intracranial pressure, depend on the site and volume of the space-occupying lesion. Anemia, leukopenia, thrombocytopenia, and their related symptoms are uncommon.
  • CNS disease with CSF involvement especially in craniopharyngeal cases is known to occur. [128]
Previous
Next

Causes

The etiology of histiocytosis disorders depends on the type of disease involved.[129] Because of the significant variation, the etiologies of HLH, ECD, and LCH are described separately.

HLH is characterized by the uncontrolled proliferation of activated lymphocytes and histiocytes secreting a large amount of inflammatory cytokines. HLH can be inherited or acquired; however, all forms of the disease have impaired function of natural killer cells and cytotoxic T cells in common. Genetic form of HCH occurs in families (FHLH) and in various inherited immune disorders, including Chédiak-Higashi syndrome 1 (CHS1), Griscelli syndrome 2 (GS2) (mutation in RAB27A), and X-linked lymphoproliferative syndrome (XLP). In most cases with acquired HLH, the immune system is normal and the disease is triggered by an infection, underlying malignancy, immune deficient disorder, or Kawasaki disease.

FHLH is a rare, genetically heterogeneous immune disorder with incidence of 0.12-1 cases per 100,000. It is inherited as an autosomal recessive disorder; thus, each sibling has a 25% chance of the disease, 50% are carriers, and 25% remain unaffected. Five genetic loci (ie, FHL1, FHL2, FHL3, FHL4, FHL5) are associated with familial HLH.

Table 1. Genetics in FHLH[130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 54, 155, 156] (Open Table in a new window)

Genetic defect/syndrome Genetic Defect Protein Frequency % FHL cases (location) Mutation Type Function
FHLH1 Unknown (9 gr 21.3-22) Rare



Pakistan



FHLH2 PRF



(10 gr 21-22)



Perforin 20-40%



Often in blacks, Turks, Japanese



>50 deletions, non-sense and missense mutations; heterozygosity for C272T, A91V substitution Pore-forming protein
FHLH3 UNC13D



(17 gr 25)



MUNC 13-4 20-30%



Worldwide, Turks, Kurds, US, Europe



>18 deep intronic mutations and large inversion Vesicle forming
FHLH4 STX 11



(6 gr 24)



Syntaxin-11 10-20%



Worldwide, Central Europe, Turkey, Saudi Arabia



Variable Vesicle transport and fusion
FHLH5 STXBP2



(19p)



MUNC 18-2 5-20%



Worldwide ,Italy, UK, Kuwait, Pakistan, North America



Multiple motatronin MUNC 18-2, impaired binding to syntaxin-11 Vesicle transport and fusion SNARE complex assembly and disassembly
Immune deficiency and albinism
Chédiak-Higashi syndrome LYST LYST Rare



Worldwide



Size function of lytic granules
Griscelli syndrome type II Rab 27A Rab 27A Rare



Northern Europe



Vesicle docking, granule movement
Hermansky-Pudlak syndrome Type II AP3B1 Rare



Worldwide



Vesicle biogenesis, protein sorting
Primary Immune Deficiencies
X-linked lymphoproliferative disease Type I SH2D1A SAP Worldwide Signal transduction, activation of lymphocytes
X-linked lymphoproliferative disease Type II BIRC4 XIAP Worldwide Inhibition of apoptosis
ITK deficiency ITK ITK Worldwide T-cell kinase

 

FHLH results in disturbance of regulatory pathways that mediate immune defense and natural termination of immune/inflammatory response. The expressions of genes associated with natural killer cells (NK-cell) functions, innate and adaptive immune responses, proapoptic proteins, and B-cell and T-cell differentiation have been shown to be down-regulated in this disorder.[150]

Some studies suggest the use of perforin expression by peripheral lymphocytes, assessment of the behavior of the 2B4 lymphocyte receptor and NK-cell activity as the bases to identify different subgroups of HLH.[143]

Mutations of MRNA splicing commonly are the underlying molecular defect in patients with FLH3. The MUNC13-4 protein primes the secondary mutation in this gene and can result in defective cellular cytotoxicity. In a study of 31 families with FHLH, at least one mutation responsible for splicing error was identified. The deep intronic mutations detected affected regulatory sequences resulting in aberrant splicing. Therefore, the UNC13D mutations appear to lead to splicing errors, which results in common symptomatologies seen in FLH3.[157]

A genomic region (ie, 9gr21) has been linked to FHLH1; however, the gene responsible for the specific product or action remains unknown.[138]

In FHLH2, gene encoding perforin, which is located on chromosome 10 (ie, 10gr21-21) has been identified. Perforin along with granzyme B are intracellular contents of lysosomal granules in cytotoxic T and NK cells, which are essential for appropriate function of microtubule organizing complex (MTOC). More than 50 mutations of perforin have been described with predominance of blacks, some degree of prevalence in Turkey, and to a lesser extent in Japan. In 62.5% of Japanese patients, the perforin mutation is the 1090-1091delCT and in the remaining 37.5%, 207delC.[134]

In Turkish patients, the perforin mutation often is Trp 374X and results in an early onset of the disease.[149]

In Italian cases, A91V sequence variant is seen with onset of the disease later in life. IN FHLH3, the UNC13D gene is located on chromosome 17 (17gr25), which encodes for the production of MUNC13-4 protein is involved. At least 18 separate mutations have been identified. Despite the genetic findings, the course of the disease is identical to those of FHLH2. MUNC13-4 protein, a member of the UNC13 family of intracellular protein, is essential for vesicle priming. In patients with FHLH3, MUNC13-4 mutation results in defects in the priming of the lytic granules containing perforin and granzymes A and B.

In FHLH4, the syntaxin 11 (STX11) gene is located on chromosome 6 (6gr24), which encodes the production of syntaxin 11. A syntaxin mutation finding is not consistent in all affected patients. Although it accounts for 14% of non-FHLH1 cases, it is more frequently found in Turkish patients (21%) and is not present in the Japanese cases.[158, 159]

In FHLH5, the STXBP2 gene is located on chromosome 19 (19p), which encodes for the protection of MUNC18-2 (ie, syntaxin binding protein 2), and STXBP2 is involved. This protein regulates intracellular trafficking and control of SNARE complex assembly and disassembly, thus exocytosis machinery.[160, 161]

Most reported cases, as expected, are consanguineous families and are due to homozygous missense mutations. The mutation has been reported in Turkish, Saudi Arabian, and central European countries.

HLH can occur in the absence of a genetic mutation or factors and conditions associated with genetic predisposition/alteration or consanguinity. Although the data is sparse, secondary HLH likely has by far greater incidences than FLH.[162]

The most common causes of secondary HLH are as follows:[163, 164, 165, 166, 167, 168, 169]

  • Infections (viral, bacterial, parasitic and fungal)
    • Epstein-Barr virus
    • Cytomegalovirus
    • Human herpes virus 8 (HHV8)
    • HIV
    • Mycoplasma mycobacteria
    • Leishmania
    • Plasmodium candida
    • Cryptococcus
    • Kala Azar
  • Immunosuppression - After organ transplantation
    • Cancer
    • T-cell lymphoma
    • Leukemias
  • Metabolic disorders
    • Lysinuric protein intolerance
    • Multiple sulfatase deficiency
    • Wolman disease
  • Autoimmune disorders - Systemic lupus erythematosus
  • Macrophage activation syndrome - Still disease

Erdheim-Chester Disease (polystatic sclerosing histiocytoses) is characterized by proliferation of histiocytes, infiltration of lipid-laden tissue macrophages and multinucleated giant cells. It predominantly affects middle-aged adults. The disease often involves long bones; however, in half of the cases, extraskeletal involvement is reported. The etiology of this disorder is not known.

In summary, the causes of most histiocytoses are not known. Factors implicated in the etiology and pathophysiology of these disorders include infections, especially viral infections;[170] cellular and immune dysfunction,[171, 172] including dysfunction of lymphocytes and cytokines;[173, 174, 175] neoplastic mechanisms; genetic factors;[176, 177, 178, 179, 180, 181, 182, 183] cellular adhesion molecules;[184, 185, 186] and their combinations.

Although HHV6 has been found in lesions of LCH, its etiologic significance has been questioned.[184, 187, 188] Extensive searches for evidence of viral infection have been unrevealing.[129]

One report from Sweden suggests an increased rate of diagnosed histiocytosis in children conceived using in vitro fertilization.[189] In FLH, distinct genetic mutations have been clearly demonstrated.

Cytokines play an important role in the physiology and biology of dendritic cells and macrophages. LCH lesions contain various cytokines.[173, 174, 175] Large amounts of cytokines are produced by CD1a+ LCH and by CD3+ T cells, including IL-2, IL-4, IL-5, and TNF-alpha, which are exclusively generated by T cells. IL-1a is derived from Langerhans cells. T cells and macrophages can produce GM-CSF and INF-alpha, whereas LCHs and macrophages produce IL-10, and T cells and macrophages produce IL-3. Macrophages produce IL-7. Eosinophils are partly responsible for the production of IL-5, INF-gamma, GM-CSF, IL-10, IL-3, and IL-4.[174, 175]

Expression of abnormal leukocyte cellular adhesion molecules in LCH has been reported.[185, 186] These molecules mediate cell-to-cell and cell-to-matrix adhesion.

Using the X-linked human androgen receptor polymerase chain reaction (PCR)-based assay to assess clonality, researchers demonstrated that all forms of LCH are clonal; therefore, LCH is a clonal neoplastic disorder. Origination from a single cell is postulated to indicate neoplasia, although it does not mean that the process is histologically malignant.[190] Using this standard, LCH is considered to be a neoplastic disease rather than a reactive disorder, as was previously proposed.[191]

The role of genetics is not well defined. The occurrence of several cases in one family is rare but has been reported.[192, 193] LCH has been reported in several monozygotic and dizygotic twins.[178, 180, 180, 181, 182, 183, 194] Some consanguinity and involvement in close relatives (cousins) has been reported.[195] Nevertheless, the relative rarity of the familial occurrence does not indicate a notable hereditary influence. Conversely, FHLH, which is transmitted as autosomal recessive trait abnormalities of genes localized to bands 9q21.2-22 and 10q21-22 (perforin), is reported in some families.[174, 175] As expected, numerous familial cases of erythrophagocytic lymphohistiocytosis have been reported.[96]

The fusion of nucleaphosmin (NPM) and anaplastic lymphoma kinase (ALK) genes that results in NPM-ALK fusion protein, which can be immunohistochemically demonstrated, is reported in malignant histiocytosis. Recently, 3 cases of histiocytosis in early infancy with enlarged liver and spleen, anemia, and thrombocytopenia are reported. In one case, analysis had revealed TPM-3-ALK fusion.[194]

Spontaneous cytotoxicity of circulating lymphocytes is observed in patients with LCH. Antibody formation to autologous erythrocyte has also been reported.[196] Given these findings, treatment with crude calf-thymus extract, although not substantially successful, was clinically devised and used.[196, 197]

A prominent feature of patients with HLH is deficiency in NK-cell function against MHC-negative K652 target cells. Patients with FHLH usually exhibit this defect at diagnosis. Patients with infection-associated hemophagocytic syndrome may have normal function, they may never have completely negative function, or they may develop negative NK-cell activity during the course of the disease.[162]

The etiologic role of impaired effector function of perforin with subsequent inability to release perforin-containing granules is demonstrated in HLH. It is similar to the mononuclear cell infiltration associated with Chediak-Higashi Syndrome and Griscelli Syndrome.[198, 199, 200]

Association of LCH with leukemias and lymphomas has been described.[201]  A study by Yokokawa et al examining the development of LCH during maintenance chemotherapy for T-cell acute lymphoblastic leukemia suggested that cells associated with both diseases arise from a common precursor cell featuring a T-cell receptor rearrangement and a single NOTCH1 mutation.[202]

Previous
 
 
Contributor Information and Disclosures
Author

Cameron K Tebbi, MD Professor of Pediatrics, Chief, Division of Pediatric Hematology-Oncology, University of South Florida College of Medicine; Director, Children's Medical Services, Pediatric Hematology/Oncology, Tampa Division, State of Florida Department of Health

Cameron K Tebbi, MD is a member of the following medical societies: American Association for Cancer Research, American Society of Pediatric Hematology/Oncology, Children's Oncology Group, International Society of Paediatric Oncology, Histiocyte Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Gary D Crouch, MD Associate Professor, Program Director of Pediatric Hematology-Oncology Fellowship, Department of Pediatrics, Uniformed Services University of the Health Sciences

Gary D Crouch, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Hematology

Disclosure: Nothing to disclose.

Chief Editor

Robert J Arceci, MD, PhD Director, Children’s Center for Cancer and Blood Disorders, Department of Hematology/Oncology, Co-Director of the Ron Matricaria Institute of Molecular Medicine, Phoenix Children’s Hospital; Editor-in-Chief, Pediatric Blood and Cancer; Professor, Department of Child Health, University of Arizona College of Medicine

Robert J Arceci, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American Association for Cancer Research, American Pediatric Society, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Acknowledgements

Gary R Jones, MD Associate Medical Director, Clinical Development, Berlex Laboratories

Gary R Jones, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Pediatric Hematology/Oncology, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Thomas W Loew, MD Clinical Professor of Pediatrics, Division Director of Pediatric Hematology/Oncology, University of Missouri Children's Hospital

Thomas W Loew, MD is a member of the following medical societies: American Academy of Pediatrics, American Academy of Pediatrics, American College of Physician Executives, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Children's Oncology Group

Disclosure: Genzyme Grant/research funds Independent contractor; Genzyme Honoraria Speaking and teaching; Amicus Grant/research funds Independent contractor; Purdue Pharmaceuticals Grant/research funds Independent contractor

References
  1. Lahey ME. Prognosis in retinucloendotheliosis in children. J Pediatr. 1962. 60:664-71.

  2. Lampert F. Langerhans cell histiocytosis. Historical perspectives. Hematol Oncol Clin North Am. 1998 Apr. 12(2):213-9. [Medline].

  3. Leverkus M, Walczak H, McLellan A, Fries HW, Terbeck G, Bröcker EB, et al. Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. Blood. 2000 Oct 1. 96(7):2628-31. [Medline].

  4. LICHTENSTEIN L. Histiocytosis X; integration of eosinophilic granuloma of bone, Letterer-Siwe disease, and Schüller-Christian disease as related manifestations of a single nosologic entity. AMA Arch Pathol. 1953 Jul. 56(1):84-102. [Medline].

  5. Chu T, D'Angio GJ, Favara BE, Ladisch S, Nesbit M, Pritchard J. Histiocytosis syndromes in children. Lancet. 1987 Jul 4. 2(8549):41-2. [Medline].

  6. Neumann MP, Frizzera G. The coexistence of Langerhans' cell granulomatosis and malignant lymphoma may take different forms: report of seven cases with a review of the literature. Hum Pathol. 1986 Oct. 17(10):1060-5. [Medline].

  7. Lipton JM. The pathogenesis, diagnosis, and treatment of histiocytosis syndromes. Pediatr Dermatol. 1983 Oct. 1(2):112-20. [Medline].

  8. Histiocytosis syndromes in children. Writing Group of the Histiocyte Society. Lancet. 1987 Jan 24. 1(8526):208-9. [Medline].

  9. Katz SI, Tamaki K, Sachs DH. Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature. 1979 Nov 15. 282(5736):324-6. [Medline].

  10. Gonzalez CL, Jaffe ES. The histiocytoses: clinical presentation and differential diagnosis. Oncology (Williston Park). 1990 Nov. 4(11):47-60; discussion 60, 62. [Medline].

  11. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol. 2000 Feb 1. 164(3):1269-76. [Medline].

  12. Steiner M, Matthes-Martin S, Attarbaschi A, Minkov M, Grois N, Unger E, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2005 Aug. 36(3):215-25. [Medline].

  13. Caux C, Liu YJ, Banchereau J. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today. 1995 Jan. 16(1):2-4. [Medline].

  14. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998 Mar 19. 392(6673):245-52. [Medline].

  15. Svensson M, Stockinger B, Wick MJ. Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. J Immunol. 1997 May 1. 158(9):4229-36. [Medline].

  16. Wilson CC, Tueting T, Ma D, et al. Activation of dendritic cells by surrogate T-cell interactions leads to enhanced costimulation, secretion of TH1-associated cytokines, and CTL inductive capacity. Ricciardi-Castagnoli. Dendritic Cells in Fundamental and Clinical Immunology. New York, NY: Plenum; 1997. 335-43.

  17. Grewal IS, Flavell RA. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today. 1996 Sep. 17(9):410-4. [Medline].

  18. Lykens J, Wessendarp M, Jordan M. Cytokine overproduction by perforin deficient mice is associated with functional alterations of antigen presenting cells. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina,. Oct 2006.

  19. Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol. 1995 Jan 1. 154(1):97-105. [Medline].

  20. Spencer D. Rare single system diseases. Paediatr Respir Rev. 2001 Mar. 2(1):63-9. [Medline].

  21. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol. 1995 May 15. 154(10):5071-9. [Medline].

  22. Scheicher C, Mehlig M, Dienes HP, Reske K. Uptake of microparticle-adsorbed protein antigen by bone marrow-derived dendritic cells results in up-regulation of interleukin-1 alpha and interleukin-12 p40/p35 and triggers prolonged, efficient antigen presentation. Eur J Immunol. 1995 Jun. 25(6):1566-72. [Medline].

  23. Sprent J, Cai Z, Brunmark A, et al. Constructing artificial antigen-presenting cells from drosophila cells in dendritic cells. Ricciardi-Castagnoli. Fundamental and Clinical Immunology. New York, NY: Plenum Press; 1997. 249-53.

  24. Steinman RM, Pack M, Inaba K. Dendritic cell development and maturation in dendritic cells. Ricciardi-Castagnol. Fundamental and Clinical Immunology. New York, NY: Plenum; 1997. 1-5.

  25. Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood. 1997 Nov 1. 90(9):3640-6. [Medline].

  26. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993 Jan 14. 328(2):106-13. [Medline].

  27. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 1991 Apr 15. 77(8):1627-52. [Medline].

  28. Buelens C, Verhasselt V, De Groote D, Thielemans K, Goldman M, Willems F. Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10. Eur J Immunol. 1997 Aug. 27(8):1848-52. [Medline].

  29. Inaba K, Inaba M, Naito M, Steinman RM. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med. 1993 Aug 1. 178(2):479-88. [Medline]. [Full Text].

  30. Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M, et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999 Jul 9. 98(1):47-58. [Medline].

  31. Björck P, Banchereau J, Flores-Romo L. CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells. Int Immunol. 1997 Mar. 9(3):365-72. [Medline].

  32. Koppi TA, Tough-Bement T, Lewinsohn DM, Lynch DH, Alderson MR. CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-derived dendritic cells. Eur J Immunol. 1997 Dec. 27(12):3161-5. [Medline].

  33. Rescigno M, Piguet V, Valzasina B, Lens S, Zubler R, French L, et al. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J Exp Med. 2000 Dec 4. 192(11):1661-8. [Medline]. [Full Text].

  34. Willems F, Amraoui Z, Vanderheyde N, Verhasselt V, Aksoy E, Scaffidi C, et al. Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood. 2000 Jun 1. 95(11):3478-82. [Medline].

  35. Romani N, Reider D, Heuer M, Ebner S, Kämpgen E, Eibl B, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996 Sep 27. 196(2):137-51. [Medline].

  36. Defrance T, Casamayor-Pallejà M, Krammer PH. The life and death of a B cell. Adv Cancer Res. 2002. 86:195-225. [Medline].

  37. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997 Jul 10. 388(6638):190-5. [Medline].

  38. Ingulli E, Mondino A, Khoruts A, Jenkins MK. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med. 1997 Jun 16. 185(12):2133-41. [Medline]. [Full Text].

  39. Reis e Sousa C, Stahl PD, Austyn JM. Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med. 1993 Aug 1. 178(2):509-19. [Medline]. [Full Text].

  40. Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 7. 211(4):669-83. [Medline]. [Full Text].

  41. Arceci RJ. The histiocytoses: the fall of the Tower of Babel. Eur J Cancer. 1999 May. 35(5):747-67; discussion 767-9. [Medline].

  42. Kelly KM, Beverley PC, Chu AC, Davenport V, Gordon I, Smith M, et al. Successful in vivo immunolocalization of Langerhans cell histiocytosis with use of a monoclonal antibody, NA1/34. J Pediatr. 1994 Nov. 125(5 Pt 1):717-22. [Medline].

  43. Carstensen H, Ornvold K. The epidemiology of Langerhans cell histiocytosis in children in Denmark 1975-89. Med Pediatr Oncol. 1993. 21:387-8.

  44. Isaacs H Jr. Fetal and neonatal histiocytoses. Pediatr Blood Cancer. 2006 Aug. 47(2):123-9. [Medline].

  45. Salotti J, Nanduri V, Windebank K. Langerhans cell histiocytosis (LCH) in children in the UK and Eire: an epidemiological survey. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina. Oct 2006.

  46. Malone M. The histiocytoses of childhood. Histopathology. 1991 Aug. 19(2):105-19. [Medline].

  47. Aricò M, Girschikofsky M, Généreau T, Klersy C, McClain K, Grois N, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer. 2003 Nov. 39(16):2341-8. [Medline].

  48. Götz G, Fichter J. Langerhans'-cell histiocytosis in 58 adults. Eur J Med Res. 2004 Nov 29. 9(11):510-4. [Medline].

  49. Nicholson HS, Egeler RM, Nesbit ME. The epidemiology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998 Apr. 12(2):379-84. [Medline].

  50. Subramanian N, Krishnakumar S, Babu K, Mohan R, Lakshmi KS, Biswas J. Adult onset Langerhans cell histiocytosis of the orbit--a case report. Orbit. 2004 Jun. 23(2):99-103. [Medline].

  51. Malpas JS. Langerhans cell histiocytosis in adults. Hematol Oncol Clin North Am. 1998 Apr. 12(2):259-68. [Medline].

  52. Minkov M, Prosch H, Steiner M, Grois N, Pötschger U, Kaatsch P, et al. Langerhans cell histiocytosis in neonates. Pediatr Blood Cancer. 2005 Nov. 45(6):802-7. [Medline].

  53. Stiakaki E, Giannakopoulou C, Kouvidi E, Bolonaki E, Kambourakis A, Lydaki E, et al. Congenital systemic Langerhans cell histiocytosis (report of two cases). Haematologia (Budap). 1997. 28(4):215-22. [Medline].

  54. Abla O, Egeler RM, Weitzman S. Langerhans cell histiocytosis: Current concepts and treatments. Cancer Treat Rev. 2010 Jun. 36(4):354-9. [Medline].

  55. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999 Dec. 17(12):3835-49. [Medline].

  56. Lucaya J. Histiocytosis X. Am J Dis Child. 1971 Apr. 121(4):289-95. [Medline].

  57. Arceci RJ Histiocytoses and disorders of the reticuloendothelial system. Histiocytoses and disorders of the reticuloendothelial system. Handin RI, Lux SE, Stossel TP. Blood: Principles and Practice of Hematology. Philadelphia, Pa: JB Lippincott; 1995. 915-46.

  58. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998 Apr. 12(2):327-38. [Medline].

  59. Janney CG, Hurt MA, Santa Cruz DJ. Deep juvenile xanthogranuloma. Subcutaneous and intramuscular forms. Am J Surg Pathol. 1991 Feb. 15(2):150-9. [Medline].

  60. Freyer DR, Kennedy R, Bostrom BC, Kohut G, Dehner LP. Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J Pediatr. 1996 Aug. 129(2):227-37. [Medline].

  61. Bergstresser PR, Toshiyuki K, Xu S. T cell-mediated maturation of dendritic cells in dendritic cells. Ricciardi-Castagnoli. Fundamental and Clinical Immunology. New York: Plenum; 1997. 65-9.

  62. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969 Jan. 87(1):63-70. [Medline].

  63. Rasool MN, Ramdial PK. Osseous localization of Rosai-Dorfman disease. J Hand Surg Br. 1996 Jun. 21(3):349-50. [Medline].

  64. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990 Feb. 7(1):19-73. [Medline].

  65. Ambati S, Chamyan G, Restrepo R, Escalon E, Fort J, Pefkarou A. Rosai-Dorfman disease following bone marrow transplantation for pre-B cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008 Sep. 51(3):433-5. [Medline].

  66. Lu D, Estalilla OC, Manning JT Jr, Medeiros LJ. Sinus histiocytosis with massive lymphadenopathy and malignant lymphoma involving the same lymph node: a report of four cases and review of the literature. Mod Pathol. 2000 Apr. 13(4):414-9. [Medline].

  67. Levine PH, Jahan N, Murari P, Manak M, Jaffe ES. Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). J Infect Dis. 1992 Aug. 166(2):291-5. [Medline].

  68. Rossbach HC, Dalence C, Wynn T, Tebbi C. Faisalabad histiocytosis mimics Rosai-Dorfman disease: brothers with lymphadenopathy, intrauterine fractures, short stature, and sensorineural deafness. Pediatr Blood Cancer. 2006 Oct 15. 47(5):629-32. [Medline].

  69. Skiljo M, García-Lora E, Tercedor J, Massare E, Esquivias J, García-Mellado V. Purely cutaneous Rosai-Dorfman disease. Dermatology. 1995. 191(1):49-51. [Medline].

  70. Foucar E, Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. An analysis of 14 deaths occurring in a patient registry. Cancer. 1984 Nov 1. 54(9):1834-40. [Medline].

  71. Komp DM. The treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Semin Diagn Pathol. 1990 Feb. 7(1):83-6. [Medline].

  72. Trizzino A, Janka G, Ueda I. Genotype-phenotype correlations in hemophagocytic lymphohistiocytosis. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina. Oct 2006.

  73. Aricò M, Janka G, Fischer A, Henter JI, Blanche S, Elinder G, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 1996 Feb. 10(2):197-203. [Medline].

  74. Ishii E, Ueda I, Shirakawa R, Yamamoto K, Horiuchi H, Ohga S, et al. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. Blood. 2005 May 1. 105(9):3442-8. [Medline].

  75. Lee SM, Sumegi J, Villanueva J. Patients of African ancestry with hemophagocytic lymphohistiocytosis share a common haplotype of PRF1 with a 50delT mutation. J Pediatr. 2006. 149:134-7.

  76. Braier J, Latella A, Lopez IS. Hepatic involvement in Langerhans cell histiocytosis. Cholestasis, sclerosing cholangitis and liver transplantation. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina. Oct 2006.

  77. Lu G, Xie ZD, Shen KL, Ye LJ, Wu RH, Liu CY, et al. Mutations in the perforin gene in children with hemophagocytic lymphohistiocytosis. Chin Med J (Engl). 2009 Dec 5. 122(23):2851-5. [Medline].

  78. Santoro A, Cannella S, Bossi G. MUNC13-4 mutations in patients with hemophagocytic lymphohistiocytosis are scattered of the functional domains of the protein. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina. Oct 2006.

  79. Aricò M, Egeler RM. Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998 Apr. 12(2):247-58. [Medline].

  80. Stark B, Hershko C, Rosen N, Cividalli G, Karsai H, Soffer D. Familial hemophagocytic lymphohistiocytosis (FHLH) in Israel. I. Description of 11 patients of Iranian-Iraqi origin and review of the literature. Cancer. 1984 Nov 15. 54(10):2109-21. [Medline].

  81. Ost A, Nilsson-Ardnor S, Henter JI. Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis. Histopathology. 1998 Apr. 32(4):310-6. [Medline].

  82. Filipovich AH. Life-threatening hemophagocytic syndromes: current outcomes with hematopoietic stem cell transplantation. Pediatr Transplant. 2005 Dec. 9 Suppl 7:87-91. [Medline].

  83. Laurencikas E, Hjorth L, Osterlunch G. Frequency and imaging characteristics of CNS abnormalities in children with hemophagocytic lymphohistiocytosis. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina. Oct 2006.

  84. Zur Stadt U, Schmidt S, Kasper B. Linkage of familial hemophagocytic lymphohistiocytosis (FHL), Type 4 to chromosome 6g24 and identification of mutations in syntaxin II. Hem Mol Genet. 2005. 14(6):827-34.

  85. Horne A, Rudd E, Ericson K. Characterization of genotype-phenotype correlations in hemophagocytic lymphohistiocytosis. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina. Oct 2006.

  86. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998 Apr. 12(2):435-44. [Medline].

  87. Filipovich AH. Hemophagocytic lymphohistiocytosis: a lethal disorder of immune regulation. J Pediatr. 1997 Mar. 130(3):337-8. [Medline].

  88. Jaffe ES, Costa J, Fauci AS, Cossman J, Tsokos M. Malignant lymphoma and erythrophagocytosis simulating malignant histiocytosis. Am J Med. 1983 Nov. 75(5):741-9. [Medline].

  89. Boyd AW, Ellis DW, Kannourakis G, Begley CG, Mackay IR, Burns GF. Activated killer cell lymphoma: an erythrophagocytic syndrome simulating histiocytic medullary histiocytosis. Pathology. 1988 Jul. 20(3):265-70. [Medline].

  90. Falini B, Pileri S, De Solas I, Martelli MF, Mason DY, Delsol G, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood. 1990 Jan 15. 75(2):434-44. [Medline].

  91. Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest. 1997 Oct 15. 100(8):1969-79. [Medline]. [Full Text].

  92. Egeler RM, D'Angio ES. Hematol Oncol Clin North Am. 12: 2.

  93. Tsuji T, Hirano T, Yamasaki H, Tsuji M, Tsuda H. A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol. 2014 May. 93(5):821-6. [Medline]. [Full Text].

  94. Yoo IH, Na H, Bae EY, Han SB, Lee SY, Jeong DC, et al. Recurrent lymphadenopathy in children with Kikuchi-Fujimoto disease. Eur J Pediatr. 2014 Apr 9. [Medline].

  95. Pilichowska ME, Pinkus JL, Pinkus GS. Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease): lesional cells exhibit an immature dendritic cell phenotype. Am J Clin Pathol. 2009 Feb. 131(2):174-82. [Medline].

  96. Kadin ME, Kamoun M, Lamberg J. Erythrophagocytic T gamma lymphoma: a clinicopathologic entity resembling malignant histiocytosis. N Engl J Med. 1981 Mar 12. 304(11):648-53. [Medline].

  97. Cooke CB, Krenacs L, Stetler-Stevenson M, Greiner TC, Raffeld M, Kingma DW, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood. 1996 Dec 1. 88(11):4265-74. [Medline].

  98. Chang KL, Arber DA. Hepatosplenic gamma delta T-cell lymphoma--not just alphabet soup. Adv Anat Pathol. 1998 Jan. 5(1):21-9. [Medline].

  99. Henter JI. Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Med Pediatr Oncol. 2002 May. 38(5):305-9. [Medline].

  100. Dorfman RF, Berry GJ. Kikuchi's histiocytic necrotizing lymphadenitis: an analysis of 108 cases with emphasis on differential diagnosis. Semin Diagn Pathol. 1988 Nov. 5(4):329-45. [Medline].

  101. Marcenaro S, Gallo F, Martini S. Defective CD107a surface expression heralds MUNC13-4 defect and discriminates between genetic subtypes of familial hemophagocytic lymphohistiocytosis. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina. Oct 2006.

  102. Zunino-Goutorbe C, Eschard C, Durlach A, Bernard P. Congenital solitary histiocytoma: a variant of Hashimoto-Pritzker histiocytosis. A retrospective study of 8 cases. Dermatology. 2008. 216(2):118-24. [Medline].

  103. Schmidt S, Eich G, Hanquinet S, Tschäppeler H, Waibel P, Gudinchet F. Extra-osseous involvement of Langerhans' cell histiocytosis in children. Pediatr Radiol. 2004 Apr. 34(4):313-21. [Medline].

  104. Hidayat AA, Mafee MF, Laver NV, Noujaim S. Langerhans' cell histiocytosis and juvenile xanthogranuloma of the orbit. Clinicopathologic, CT, and MR imaging features. Radiol Clin North Am. 1998 Nov. 36(6):1229-40, xii. [Medline].

  105. Maccheron LJ, McNab AA, Elder J, Selva D, Martin FJ, Clement CI, et al. Ocular adnexal Langerhans cell histiocytosis clinical features and management. Orbit. 2006 Sep. 25(3):169-77. [Medline].

  106. Tsai JH, Galaydh F, Ching SS. Anterior uveitis and iris nodules that are associated with Langerhans cell histiocytosis. Am J Ophthalmol. 2005 Dec. 140(6):1143-5. [Medline].

  107. AVERY ME, MCAFEE JG, GUILD HG. The course and prognosis of reticuloendotheliosis (eosinophilic granuloma, Schüller-Christian disease and Letterer-Siwe disease); a study of forty cases. Am J Med. 1957 Apr. 22(4):636-52. [Medline].

  108. Sims DG. Histiocytosis X; follow-up of 43 cases. Arch Dis Child. 1977 Jun. 52(6):433-40. [Medline]. [Full Text].

  109. Greenberger JS, Cassady JR, Jaffe N, Vawter G, Crocker AC. Radiation therapy in patients with histiocytosis: management of diabetes insipidus and bone lesions. Int J Radiat Oncol Biol Phys. 1979 Oct. 5(10):1749-55. [Medline].

  110. Braunstein GD, Kohler PO. Endocrine manifestations of histiocytosis. Am J Pediatr Hematol Oncol. 1981 Spring. 3(1):67-75. [Medline].

  111. Rosenzweig KE, Arceci RJ, Tarbell NJ. Diabetes insipidus secondary to Langerhans' cell histiocytosis: is radiation therapy indicated?. Med Pediatr Oncol. 1997 Jul. 29(1):36-40. [Medline].

  112. Kaltsas GA, Powles TB, Evanson J, Plowman PN, Drinkwater JE, Jenkins PJ, et al. Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab. 2000 Apr. 85(4):1370-6. [Medline].

  113. Unlü F, Gürses N, Seçkin T, Unal T. Multifocal eosinophilic granuloma with sequential periodontitis-like lesions. J Clin Periodontol. 1997 Jun. 24(6):384-7. [Medline].

  114. McDonald JS, Miller RL, Bernstein ML, Olson JW. Histiocytosis X: a clinical presentation. J Oral Pathol. 1980 Nov. 9(6):342-9. [Medline].

  115. Lookingbill DP. Histiocytosis X confined to the skin of the scalp. J Am Acad Dermatol. 1984 Jun. 10(6):968-9. [Medline].

  116. Hashimoto K, Schachner LA, Huneiti A, Tanaka K. Pagetoid self-healing Langerhans cell histiocytosis in an infant. Pediatr Dermatol. 1999 Mar-Apr. 16(2):121-7. [Medline].

  117. Johno M, Oishi M, Kohmaru M, Yoshimura K, Ono T. Langerhans cell histiocytosis presenting as a varicelliform eruption over the entire skin. J Dermatol. 1994 Mar. 21(3):197-204. [Medline].

  118. Munn S, Chu AC. Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am. 1998 Apr. 12(2):269-86. [Medline].

  119. Hashimoto K, Pritzker MS. Electron microscopic study of reticulohistiocytoma. An unusual case of congenital, self-healing reticulohistiocytosis. Arch Dermatol. 1973 Feb. 107(2):263-70. [Medline].

  120. Ha SY, Helms P, Fletcher M, Broadbent V, Pritchard J. Lung involvement in Langerhans' cell histiocytosis: prevalence, clinical features, and outcome. Pediatrics. 1992 Mar. 89(3):466-9. [Medline].

  121. Vassallo R, Ryu JH, Colby TV, Hartman T, Limper AH. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med. 2000 Jun 29. 342(26):1969-78. [Medline].

  122. Donnelly LF, Frush DP. Langerhans' cell histiocytosis showing low-attenuation mediastinal mass and cystic lung disease. AJR Am J Roentgenol. 2000 Mar. 174(3):877-8. [Medline].

  123. Motoi M, Helbron D, Kaiserling E, Lennert K. Eosinophilic granuloma of lymph nodes--a variant of histiocytosis X. Histopathology. 1980 Nov. 4(6):585-606. [Medline].

  124. Sacks SH, Hall I, Ragge N, Pritchard J. Chronic dermal sinuses as a manifestation of histiocytosis X. Br Med J (Clin Res Ed). 1986 Apr 26. 292(6528):1097-8. [Medline]. [Full Text].

  125. Lee BH, George S, Kutok JL. Langerhans cell histiocytosis involving the thymus. A case report and review of the literature. Arch Pathol Lab Med. 2003 Jul. 127(7):e294-7. [Medline].

  126. Rosenfield NS, Abrahams J, Komp D. Brain MR in patients with Langerhans cell histiocytosis: findings and enhancement with Gd-DTPA. Pediatr Radiol. 1990. 20(6):433-6. [Medline].

  127. Beni-Adani L, Sainte-Rose C, Zerah M, Brunelle F, Constantini S, Renier D, et al. Surgical implications of the thickened pituitary stalk accompanied by central diabetes insipidus. J Neurosurg. 2005 Aug. 103(2 Suppl):142-7. [Medline].

  128. Histiocyte Society. Report of the Histiocyte Society workshop on "Central nervous system (CNS) disease in Langerhans cell histiocytosis (LCH)". Med Pediatr Oncol. 1997 Aug. 29(2):73-8. [Medline].

  129. Mierau GW, Wills EJ, Steele PO. Ultrastructural studies in Langerhans cell histiocytosis: a search for evidence of viral etiology. Pediatr Pathol. 1994 Sep-Oct. 14(5):895-904. [Medline].

  130. Sieni E, Cetica V, Santoro A, Beutel K, Mastrodicasa E, Meeths M, et al. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. J Med Genet. 2011 May. 48(5):343-52. [Medline].

  131. Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011 Nov 24. 118(22):5794-8. [Medline].

  132. Cetica V, Santoro A, Gilmour KC, Sieni E, Beutel K, Pende D. STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5. J Med Genet. 2010 Sep. 47(9):595-600. [Medline].

  133. Molleran Lee S, Villanueva J, Sumegi J, Zhang K, Kogawa K, Davis J, et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet. 2004 Feb. 41(2):137-44. [Medline]. [Full Text].

  134. Molleran Lee S, Villanueva J, Sumegi J, Zhang K, Kogawa K, Davis J, et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet. 2004 Feb. 41(2):137-44. [Medline]. [Full Text].

  135. Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010 Aug 19. 116(7):1079-82. [Medline]. [Full Text].

  136. Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, et al. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer. 2010 Jul 15. 55(1):134-40. [Medline].

  137. Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 23. 116(26):5824-31. [Medline].

  138. Ohadi M, Lalloz MR, Sham P, Zhao J, Dearlove AM, Shiach C, et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am J Hum Genet. 1999 Jan. 64(1):165-71. [Medline]. [Full Text].

  139. Risma KA, Frayer RW, Filipovich AH, Sumegi J. Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. J Clin Invest. 2006 Jan. 116(1):182-92. [Medline].

  140. Busiello R, Adriani M, Locatelli F, et al. A typical features of familial hemophagocytic lymphohistiocytosis. Blood. 2004. 103:4610-12.

  141. Clementi R, Emmi L, Maccario R, Liotta F, Moretta L, Danesino C. Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood. 2002 Sep 15. 100(6):2266-7. [Medline].

  142. Göransdotter Ericson K, Fadeel B, Nilsson-Ardnor S, Söderhäll C, Samuelsson A, Janka G, et al. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. Am J Hum Genet. 2001 Mar. 68(3):590-7. [Medline]. [Full Text].

  143. Arico M, Allen M, Brusa S, Clementi R, Pende D, Maccario R, et al. Haemophagocytic lymphohistiocytosis: proposal of a diagnostic logarithm based on perforin expression. Br J Haemo. 2002. 119:180-188.

  144. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002 Jan 1. 99(1):61-6. [Medline].

  145. Feldmann J, Le Deist F, Ouachée-Chardin M, Certain S, Alexander S, Quartier P. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. Br J Haematol. 2002 Jun. 117(4):965-72. [Medline].

  146. Suga N, Takada H, Nomura A, Ohga S, Ishii E, Ihara K, et al. Perforin defects of primary haemophagocytic lymphohistiocytosis in Japan. Br J Haematol. 2002 Feb. 116(2):346-9. [Medline].

  147. Ueda I, Morimoto A, Inaba T, Yagi T, Hibi S, Sugimoto T, et al. Characteristic perforin gene mutations of haemophagocytic lymphohistiocytosis patients in Japan. Br J Haematol. 2003 May. 121(3):503-10. [Medline].

  148. Clementi R, Locatelli F, Dupré L, Garaventa A, Emmi L, Bregni M. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood. 2005 Jun 1. 105(11):4424-8. [Medline].

  149. Zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, Janka G. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat. 2006 Jan. 27(1):62-8. [Medline].

  150. Ueda I, Kurokawa Y, Koike K, Ito S, Sakata A, Matsumora T. Late-onset cases of familial hemophagocytic lymphohistiocytosis with missense perforin gene mutations. Am J Hematol. 2007 Jun. 82(6):427-32. [Medline].

  151. Dufourcq-Lagelouse R, Pastural E, Barrat FJ, Feldmann J, Le Deist F, Fischer A, et al. Genetic basis of hemophagocytic lymphohistiocytosis syndrome (Review). Int J Mol Med. 1999 Aug. 4(2):127-33. [Medline].

  152. Meeths M, Chiang SC, Wood SM, Entesarian M, Schlums H, Bang B. Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood. 2011 Nov 24. 118(22):5783-93. [Medline].

  153. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol. 1991 Feb. 18(1):29-33. [Medline].

  154. Cetica V, Pende D, Griffiths GM, Aricò M. Molecular basis of familial hemophagocytic lymphohistiocytosis. Haematologica. 2010 Apr. 95(4):538-41. [Medline]. [Full Text].

  155. [Guideline] Zur Stadt U, Rohr J, Seifert W, et al. Familial hemophagocytic lymphohistiocytosis Type 5 (FHL5) is caused by mutations in MUNC 18-2 and impaired binding to syntaxin II. AJHG. 2009. 85(4):482-92.

  156. Cote M, Menager MM, Burgess A, et al. MUNC 18-2 deficiency causes familial hemophagocytic lymphohistiocytosis Type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest. 2009. 119(12):3765-73.

  157. Santoro A, Cannella S, Trizzino A, Bruno G, De Fusco C, Notarangelo LD. Mutations affecting mRNA splicing are the most common molecular defect in patients with familial hemophagocytic lymphohistiocytosis type 3. Haematologica. 2008 Jul. 93(7):1086-90. [Medline].

  158. Rudd E, Göransdotter Ericson K, Zheng C, Uysal Z, Ozkan A, Gürgey A. Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet. 2006 Apr. 43(4):e14. [Medline].

  159. Yamamoto K, Ishii E, Horiuchi H, et al. Mutations of syntaxin 11 and SNAP23 genes as causes of familial hemophagocytic lymphohistiocytosis were not found in Japanese people. J Hum Genet. 2005. 50:600-3.

  160. Brochetta C, Vita F, Tiwari N, Scandiuzzi L, Soranzo MR, Guérin-Marchand C. Involvement of Munc18 isoforms in the regulation of granule exocytosis in neutrophils. Biochim Biophys Acta. 2008 Oct. 1783(10):1781-91. [Medline].

  161. Martin-Verdeaux S, Pombo I, Iannascoli B, Roa M, Varin-Blank N, Rivera J. Evidence of a role for Munc18-2 and microtubules in mast cell granule exocytosis. J Cell Sci. 2003 Jan 15. 116(Pt 2):325-34. [Medline].

  162. Janka G. Hemophagocytic lymphohistiocytosis: when the immune system runs amok. Klin Padiatr. 2009 Sep. 221(5):278-85. [Medline].

  163. Farber L, Blum L, Kerob D, et al. Human herpes virus 8-associated hemophagocytic lymphohistiocytosis in human immunodeficiency-infected patients. Clin Infect Dis. 2003. 37(2):285-91.

  164. Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2007 Aug. 29(8):569-73. [Medline].

  165. Srinivas R, Dutta U, Poomachandra KS et al. Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis: case report and systematic review. J Infection. 2008. 56(5):282-5.

  166. Granert C, Elinder G, Ost A, Henter JI. Kala-azar in a one-year-old Swedish child. Diagnostic difficulties because of active hemophagocytosis. Acta Paediatr. 1993 Sep. 82(9):794-6. [Medline].

  167. Phillips J, Staszewski H, Garrison M. Successful treatment of secondary hemophagocytic lymphohistiocytosis in a patient with disseminated histioplasmosis. Hematology. 2008. 13(5):282-5.

  168. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus related hemophagocytic lymphohistiocytosis with immunotherapy. Blood. 1999. 93(6):1869-74.

  169. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002 Dec. 44(3):259-72. [Medline].

  170. Leahy MA, Krejci SM, Friednash M, Stockert SS, Wilson H, Huff JC, et al. Human herpesvirus 6 is present in lesions of Langerhans cell histiocytosis. J Invest Dermatol. 1993 Nov. 101(5):642-5. [Medline].

  171. Hage C, Willman CL, Favara BE, Isaacson PG. Langerhans' cell histiocytosis (histiocytosis X): immunophenotype and growth fraction. Hum Pathol. 1993 Aug. 24(8):840-5. [Medline].

  172. Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH, et al. Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med. 1994 Jul 21. 331(3):154-60. [Medline].

  173. Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer Suppl. 1994 Sep. 23:S37-40. [Medline]. [Full Text].

  174. Egeler RM, Favara BA, van Meurs M,et al. Cytokine profile in Langerhans cell histiocytosis. Presented at: 15th Annual Meeting of the Histiocyte Society. 1999.

  175. Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E. Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood. 1999 Dec 15. 94(12):4195-201. [Medline].

  176. Ornvold K, Carstensen H, Larsen JK, Christensen IJ, Ralfkiaer E. Flow cytometric DNA analysis of lesions from 18 children with langerhans cell histiocytosis (histiocytosis x). Am J Pathol. 1990 Jun. 136(6):1301-7. [Medline]. [Full Text].

  177. Katz AM, Rosenthal D, Jakubovic HR, Pai RK, Quinonez GE, Sauder DN. Langerhans cell histiocytosis in monozygotic twins. J Am Acad Dermatol. 1991 Jan. 24(1):32-7. [Medline].

  178. Yu RC, Chu AC. Lack of T-cell receptor gene rearrangements in cells involved in Langerhans cell histiocytosis. Cancer. 1995 Mar 1. 75(5):1162-6. [Medline].

  179. Corbeel L. Langerhans histiocytosis, haemophagocytic syndrome and Epstein-Barr virus infection. Eur J Pediatr. 2004 Sep. 163(9):570-1. [Medline].

  180. Chen CJ, Ho TY, Lu JJ, Sheu LF, Lee SY, Tien CH, et al. Identical twin brothers concordant for Langerhans' cell histiocytosis and discordant for Epstein-Barr virus-associated haemophagocytic syndrome. Eur J Pediatr. 2004 Sep. 163(9):536-9. [Medline].

  181. Kuwabara S, Takahashi M. Eosinophilic granuloma of the skull in identical twins--case report. Neurol Med Chir (Tokyo). 1990 Dec. 30(13):1043-6. [Medline].

  182. Halton J, Whitton A, Wiernikowski J, Barr RD. Disseminated Langerhans cell histiocytosis in identical twins unresponsive to recombinant human alpha-interferon and total body irradiation. Am J Pediatr Hematol Oncol. 1992 Aug. 14(3):269-72. [Medline].

  183. Mader I, Stock KW, Radue EW, Steinbrich W. Langerhans cell histiocytosis in monocygote twins: case reports. Neuroradiology. 1996 Feb. 38(2):163-5. [Medline].

  184. Ruco LP, Stoppacciaro A, Vitolo D, Uccini S, Baroni CD. Expression of adhesion molecules in Langerhans' cell histiocytosis. Histopathology. 1993 Jul. 23(1):29-37. [Medline].

  185. de Graaf JH, Tamminga RY, Kamps WA, Timens W. Expression of cellular adhesion molecules in Langerhans cell histiocytosis and normal Langerhans cells. Am J Pathol. 1995 Oct. 147(4):1161-71. [Medline]. [Full Text].

  186. de Graaf JH, Tamminga RY, Kamps WA, Timens W. Langerhans' cell histiocytosis: expression of leukocyte cellular adhesion molecules suggests abnormal homing and differentiation. Am J Pathol. 1994 Mar. 144(3):466-72. [Medline]. [Full Text].

  187. McClain K, Herring RA, et al. Evaluation of PET scans to ascertain sites of active disease in Langerhans celll histiocytosis: comparison to conventional radiography and bone scans. Presented at: 21st Annual Meeting of the Histiocyte Society. September 2005.

  188. Slacmeuler M, Geissmann Y, Lepelletier JC, et al. Lack of association between Langerhans cell histiocytosis and human herpes virus 6. Presented at: 15th Annual of the Meeting Histiocyte Society. 1999.

  189. Källén B, Finnström O, Nygren KG, Olausson PO. In vitro fertilization in Sweden: child morbidity including cancer risk. Fertil Steril. 2005 Sep. 84(3):605-10. [Medline].

  190. Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 1985 Apr. 45(4):1437-43. [Medline].

  191. Komp DM. Langerhans cell histiocytosis. N Engl J Med. 1987 Mar 19. 316(12):747-8. [Medline].

  192. Shahla A, Parvaneh V, Hossein HD. Langerhans cells histiocytosis in one family. Pediatr Hematol Oncol. 2004 Jun. 21(4):313-20. [Medline].

  193. Dufour C, Lanciotti M, Micalizzi C, Valetto A, Haupt R. Non-identical twin sisters concordant for Langerhans cell histiocytosis and discordant for secondary acute promyelocytic leukemia. Med Pediatr Oncol. 2001 Jul. 37(1):70-2. [Medline].

  194. Chan JK, Lamant L, Algar E, Delsol G, Tsang WY, Lee KC, et al. ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood. 2008 Oct 1. 112(7):2965-8. [Medline].

  195. Arico M, Bossi G, Branch del Prever A, et al. Langerhans cell histiocytosis in twins: an update. Presented at: 15th. Annual Meeting, of the Histiocyte Society. 1999.

  196. Osband ME, Lipton JM, Lavin P, Levey R, Vawter G, Greenberger JS, et al. Histiocytosis-X. N Engl J Med. 1981 Jan 15. 304(3):146-53. [Medline].

  197. Ceci A, de Terlizzi M, Toma MG, Calculli G, Caputo R, Castello M, et al. Heterogeneity of immunological patterns in Langerhan's histiocytosis and response to crude calf thymic extract in 11 patients. Med Pediatr Oncol. 1988. 16(2):111-5. [Medline].

  198. Filipovich AH, Mathur A, Kamat D, Kersey JH, Shapiro RS. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency. 1994. 5(2):91-112. [Medline].

  199. Pastural E, Barrat FJ, Dufourcq-Lagelouse R, Certain S, Sanal O, Jabado N, et al. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat Genet. 1997 Jul. 16(3):289-92. [Medline].

  200. Aricò M, Danesino C, Pende D, Moretta L. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol. 2001 Sep. 114(4):761-9. [Medline].

  201. Egeler RM, Neglia JP, Aricò M, Favara BE, Heitger A, Nesbit ME, et al. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin North Am. 1998 Apr. 12(2):369-78. [Medline].

  202. Yokokawa Y, Taki T, Chinen Y, et al. Unique clonal relationship between T-cell acute lymphoblastic leukemia and subsequent Langerhans cell histiocytosis with TCR rearrangement and NOTCH1 mutation. Genes Chromosomes Cancer. 2015 Jul. 54 (7):409-17. [Medline].

  203. Brown CW, Jarvis JG, Letts M, Carpenter B. Treatment and outcome of vertebral Langerhans cell histiocytosis at the Children's Hospital of Eastern Ontario. Can J Surg. 2005 Jun. 48(3):230-6. [Medline]. [Full Text].

  204. Sai S, Fujii K, Masui F, Kida Y. Solitary eosinophilic granuloma of the sternum. J Orthop Sci. 2005. 10(1):108-11. [Medline].

  205. Titgemeyer C, Grois N, Minkov M, Flucher-Wolfram B, Gatterer-Menz I, Gadner H. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 2001 Aug. 37(2):108-14. [Medline].

  206. Hicks J, Flaitz CM. Langerhans cell histiocytosis: current insights in a molecular age with emphasis on clinical oral and maxillofacial pathology practice. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Aug. 100(2 Suppl):S42-66. [Medline].

  207. Sikic J, Vukojevic N, Popovic-Suic S, Katusic D. Intraocular histiocytosis in a 12-year-old girl without systemic disease. Coll Antropol. 2005. 29 Suppl 1:119-21. [Medline].

  208. Braier J, Latella A, Balancini B, Castaños C, Goldberg J. Isolated pulmonary Langerhans cell histiocytosis presenting with recurrent pneumothorax. Pediatr Blood Cancer. 2007 Feb. 48(2):241-4. [Medline].

  209. Monos T, Levy J, Lifshitz T, Yagev R, Maor E. Isolated congenital histiocytosis in the palpebral conjunctiva in a newborn. Am J Ophthalmol. 2005 Apr. 139(4):728-30. [Medline].

  210. Matsubayashi T, Miwa Y, Saito I, Matsubayashi R. KL-6: marker for pulmonary involvement in Langerhans cell histiocytosis in infants. J Pediatr Hematol Oncol. 2004 Sep. 26(9):584-6. [Medline].

  211. Grois N, Prosch H, Waldhauser F, Minkov M, Strasser G, Steiner M, et al. Pineal gland abnormalities in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004 Sep. 43(3):261-6. [Medline].

  212. Cagli S, Oktar N, Demirtas E. Langerhans' cell histiocytosis of the temporal lobe and pons. Br J Neurosurg. 2004 Apr. 18(2):174-80. [Medline].

  213. Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med. 2008 Jan. 14(1):81-7. [Medline].

  214. Allen CE, McClain KL. Interleukin-17A is not expressed by CD207+ cells in Langerhans cell histiocytosis lesions. Nat Med. 2009. 15:483-484.

  215. Laurencikas E, Stalemark H, et al. Incidence of abnormal magnetic resonance imaging findings of the central nervous system in children with Langerhans cell histiocytosis. Presented at: 21st Annual Meeting of the Histiocyte Society,Vancouver, British Columbia Canada. September 2005.

  216. Azouz EM, Saigal G, Rodriguez MM, Podda A. Langerhans' cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol. 2005 Feb. 35(2):103-15. [Medline].

  217. Mueller W, Eiber M, Schiedhauer K, Coppenrath E, Schwaiger M, Bartenstein P, et al. General Clinical Specialties MTAII:Pediatrics Posters PET/MRI in pediatric histiocytosis. J Nucl Med. 2012. 53(Supplement 1):2191.

  218. Ribeiro MJ, Idbaih A, Thomas C, Remy P, Martin-Duverneuil N, Samson Y, et al. 18F-FDG PET in neurodegenerative Langerhans cell histiocytosis : results and potential interest for an early diagnosis of the disease. J Neurol. 2008 Apr. 255(4):575-80. [Medline].

  219. Schmitz L, Favara BE. Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998 Apr. 12(2):221-46. [Medline].

  220. Favara BE, Jaffe R. Pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1987 Mar. 1(1):75-97. [Medline].

  221. Risdall RJ, Dehner LP, Duray P, Kobrinsky N, Robison L, Nesbit ME Jr. Histiocytosis X (Langerhans' cell histiocytosis). Prognostic role of histopathology. Arch Pathol Lab Med. 1983 Feb. 107(2):59-63. [Medline].

  222. Nezelof C, Basset F, Rousseau MF. Histiocytosis X histogenetic arguments for a Langerhans cell origin. Biomedicine. 1973 Sep. 18(5):365-71. [Medline].

  223. Favara BE, Feller AC, Pauli M, Jaffe ES, Weiss LM, Arico M, et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol. 1997 Sep. 29(3):157-66. [Medline].

  224. Favara BE, Steele A. Langerhans cell histiocytosis of lymph nodes: a morphological assessment of 43 biopsies. Pediatr Pathol Lab Med. 1997 Sep-Oct. 17(5):769-87. [Medline].

  225. Dehner LP. Morphologic findings in the histiocytic syndromes. Semin Oncol. 1991 Feb. 18(1):8-17. [Medline].

  226. Egeler RM, Neglia JP, Puccetti DM, Brennan CA, Nesbit ME. Association of Langerhans cell histiocytosis with malignant neoplasms. Cancer. 1993 Feb 1. 71(3):865-73. [Medline].

  227. Mierau GW, Favara BE, Brenman JM. Electron microscopy in histiocytosis X. Ultrastruct Pathol. 1982 Apr-Jun. 3(2):137-42. [Medline].

  228. Wood PM, Bunge RP. The origin of remyelinating cells in the adult central nervous system: the role of the mature oligodendrocyte. Glia. 1991. 4(2):225-32. [Medline].

  229. Krenács L, Tiszalvicz L, Krenács T, Boumsell L. Immunohistochemical detection of CD1A antigen in formalin-fixed and paraffin-embedded tissue sections with monoclonal antibody 010. J Pathol. 1993 Oct. 171(2):99-104. [Medline].

  230. Emile JF, Wechsler J, Brousse N, Boulland ML, Cologon R, Fraitag S, et al. Langerhans' cell histiocytosis. Definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. Am J Surg Pathol. 1995 Jun. 19(6):636-41. [Medline].

  231. Broadbent V, Gadner H, Komp DM, Ladisch S. {Guideline} Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with Langerhans cell histiocytosis. Clinical Writing Group of the Histiocyte Society. Med Pediatr Oncol. 1989. 17(6):492-5. [Medline].

  232. Bergmann M, Yuan Y, Brück W, Palm KV, Rohkamm R. Solitary Langerhans cell histiocytosis lesion of the parieto-occipital lobe: a case report and review of the literature. Clin Neurol Neurosurg. 1997 Feb. 99(1):50-5. [Medline].

  233. Surico G, Muggeo P, Muggeo V, Conti V, Novielli C, Romano A, et al. Ear involvement in childhood Langerhans' cell histiocytosis. Head Neck. 2000 Jan. 22(1):42-7. [Medline].

  234. Hashimoto K, Kagetsu N, Taniguchi Y, Weintraub R, Chapman-Winokur RL, Kasiborski A. Immunohistochemistry and electron microscopy in Langerhans cell histiocytosis confined to the skin. J Am Acad Dermatol. 1991 Dec. 25(6 Pt 1):1044-53. [Medline].

  235. Kapila PK, Grant-Kels JM, Allred C, Forouhar F, Capriglione AM. Congenital, spontaneously regressing histiocytosis: case report and review of the literature. Pediatr Dermatol. 1985 Jul. 2(4):312-7. [Medline].

  236. Seyrig F, Emile JF, et al. Thymic involvement in LCH. A survey of 12 cases. Presented at: 21st Annual Meeting of the Histiocyte Society; Vancouver, British Columbia, Canada. September 2005.

  237. Smets A, Mortelé K, de Praeter G, François O, Benoit Y, Kunnen M. Pulmonary and mediastinal lesions in children with Langerhans cell histiocytosis. Pediatr Radiol. 1997 Nov. 27(11):873-6. [Medline].

  238. Yule SM, Hamilton JR, Windebank KP. Recurrent pneumomediastinum and pneumothorax in Langerhans cell histiocytosis. Med Pediatr Oncol. 1997 Aug. 29(2):139-42. [Medline].

  239. Barthez MA, Araujo E, Donadieu J. Langerhans cell histiocytosis and the central nervous system in childhood: evolution and prognostic factors. Results of a collaborative study. J Child Neurol. 2000 Mar. 15(3):150-6. [Medline].

  240. Sivalingam S, Corkill G, Ellis WG, Claiche JR. Focal eosinophilic granuloma of the temporal lobe. Case report. J Neurosurg. 1977 Dec. 47(6):941-5. [Medline].

  241. Greenwood SM, Martin JS, Towfighi J. Unifocal eosinophilic granuloma of the temporal lobe. Surg Neurol. 1982 Jun. 17(6):441-4. [Medline].

  242. Moscinski LC, Kleinschmidt-DeMasters BK. Primary eosinophilic granuloma of frontal lobe. Diagnostic use of S-100 protein. Cancer. 1985 Jul 15. 56(2):284-8. [Medline].

  243. Penar PL, Kim JH, Chyatte D. Solitary eosinophilic granuloma of the frontal lobe. Neurosurgery. 1987 Oct. 21(4):566-8. [Medline].

  244. Itoh H, Waga S, Kojima T, Hoshino T. Solitary eosinophilic granuloma in the frontal lobe: case report. Neurosurgery. 1992 Feb. 30(2):295-8. [Medline].

  245. van der Knaap MS, Arts WF, Garbern JY, Hedlund G, Winkler F, Barbosa C, et al. Cerebellar leukoencephalopathy: most likely histiocytosis-related. Neurology. 2008 Oct 21. 71(17):1361-7. [Medline].

  246. Hund E, Steiner H, Jansen O, Sieverts H, Sohl G, Essig M. Treatment of cerebral Langerhans cell histiocytosis. J Neurol Sci. 1999 Dec 15. 171(2):145-52. [Medline].

  247. Dunger DB, Broadbent V, Yeoman E, Seckl JR, Lightman SL, Grant DB, et al. The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. N Engl J Med. 1989 Oct 26. 321(17):1157-62. [Medline].

  248. Kaplan KJ, Goodman ZD, Ishak KG. Liver involvement in Langerhans' cell histiocytosis: a study of nine cases. Mod Pathol. 1999 Apr. 12(4):370-8. [Medline].

  249. Nanduri VR, Kelly K, Malone M, Milla P, Pritchard J. Colon involvement in Langerhans' cell histiocytosis. J Pediatr Gastroenterol Nutr. 1999 Oct. 29(4):462-6. [Medline].

  250. Nihei K, Terashima K, Aoyama K, Imai Y, Sato H. Benign histiocytosis X of stomach. Previously undescribed lesion. Acta Pathol Jpn. 1983 May. 33(3):577-88. [Medline].

  251. Idlibi O, Hamoudi AB. Primary histiocytosis X of bowel. Pediatr Pathol. 1984. 2:492A.

  252. Egeler RM, Schipper ME, Heymans HS. Gastrointestinal involvement in Langerhans' cell histiocytosis (Histiocytosis X): a clinical report of three cases. Eur J Pediatr. 1990 Feb. 149(5):325-9. [Medline].

  253. Yu RC, Attra A, Quinn CM, Krausz T, Chu AC. Multisystem Langerhans' cell histiocytosis with pancreatic involvement. Gut. 1993 Apr. 34(4):570-2. [Medline]. [Full Text].

  254. Batey CA, Samayoa LM. Progressive Langerhans' cell histiocytosis presenting as a primary penile lesion. J Urol. 2002 Mar. 167(3):1433-4. [Medline].

  255. Montero AJ, Díaz-Montero CM, Malpica A, Ramirez PT, Kavanagh JJ. Langerhans cell histiocytosis of the female genital tract: a literature review. Int J Gynecol Cancer. 2003 May-Jun. 13(3):381-8. [Medline].

  256. Dietrich JE, Edwards C, Laucirica R, Kaufman RH. Langerhans cell histiocytosis of the vulva: two case reports. J Low Genit Tract Dis. 2004 Apr. 8(2):147-9. [Medline].

  257. Galluzzo L, Rosso D, Braier J. Bone marrow histological findings of LCH patients with hematological involvement. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina,. Oct 2006.

  258. Muscolo DL, Slullitel G, Ranalletta M, Aponte-Tinao LA, Ayerza MA. Spontaneous remission of massive solitary eosinophilic granuloma of the femur. J Pediatr Orthop. 2003 Nov-Dec. 23(6):763-5. [Medline].

  259. Yamaguchi S, Oki S, Kurisu K. Spontaneous regression of Langerhans cell histiocytosis: a case report. Surg Neurol. 2004 Aug. 62(2):136-40; discussion 140-1. [Medline].

  260. Rajendram R, Rose G, Luthert P, Plowman P, Pearson A. Biopsy-confirmed spontaneous resolution of orbital langerhans cell histiocytosis. Orbit. 2005 Mar. 24(1):39-41. [Medline].

  261. Rigaud C, Barkaoui MA, Thomas C, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol. 2016 Jun 7. [Medline].

  262. Duan MH, Han X, Li J, et al. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study. Leuk Res. 2016 Mar. 42:43-6. [Medline].

  263. McLelland J, Broadbent V, Yeomans E, Malone M, Pritchard J. Langerhans cell histiocytosis: the case for conservative treatment. Arch Dis Child. 1990 Mar. 65(3):301-3. [Medline]. [Full Text].

  264. Ladisch S, Gadner H, Aricò M, Broadbent V, Grois N, Jacobson A, et al. LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society. Med Pediatr Oncol. 1994. 23(2):107-10. [Medline].

  265. Ladisch S, Gadner H. Treatment of Langerhans cell histiocytosis--evolution and current approaches. Br J Cancer Suppl. 1994 Sep. 23:S41-6. [Medline]. [Full Text].

  266. Arceci RJ. Comments from the Editor-in-Chief. J Pediatr Hematol Oncol. 1999 Jan-Feb. 21(1):1-2. [Medline].

  267. Arceci RJ. Treatment options--commentary. Br J Cancer Suppl. 1994 Sep. 23:S58-60. [Medline]. [Full Text].

  268. Hoeger PH, Nanduri VR, Harper JI, Atherton DA, Pritchard J. Long term follow up of topical mustine treatment for cutaneous langerhans cell histiocytosis. Arch Dis Child. 2000 Jun. 82(6):483-7. [Medline]. [Full Text].

  269. Sheehan MP, Atherton DJ, Broadbent V, Pritchard J. Topical nitrogen mustard: an effective treatment for cutaneous Langerhans cell histiocytosis. J Pediatr. 1991 Aug. 119(2):317-21. [Medline].

  270. Mahmoud HH, Wang WC, Murphy SB. Cyclosporine therapy for advanced Langerhans cell histiocytosis. Blood. 1991 Feb 15. 77(4):721-5. [Medline].

  271. Sato Y, Ikeda Y, Ito E, Miyano T, Kawauchi K, Yokoyama M, et al. Histiocytosis X: successful treatment with recombinant interferon-alpha A. Acta Paediatr Jpn. 1990 Apr. 32(2):151-4. [Medline].

  272. Ladisch S, Ho W, Matheson D, Pilkington R, Hartman G. Immunologic and clinical effects of repeated blood exchange in familial erythrophagocytic lymphohistiocytosis. Blood. 1982 Oct. 60(4):814-21. [Medline].

  273. D'Angio GJ. Langerhans cell histiocytosis and etoposide: risks vs. benefits. Med Pediatr Oncol. 1994. 23(2):69-71. [Medline].

  274. Weitzman S, Wayne AS, Arceci R, Lipton JM, Whitlock JA. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol. 1999 Nov. 33(5):476-81. [Medline].

  275. Saven A, Foon KA, Piro LD. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Ann Intern Med. 1994 Sep 15. 121(6):430-2. [Medline].

  276. Saven A, Figueroa ML, Piro LD, Rosenblatt JD. 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med. 1993 Sep 2. 329(10):734-5. [Medline].

  277. Dimopoulos MA, Theodorakis M, Kostis E, Papadimitris C, Moulopoulos LA, Anastasiou-Nana M. Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine. Leuk Lymphoma. 1997 Mar. 25(1-2):187-9. [Medline].

  278. Randrianasolo MP, Beylot-Barry M, Vergier B, Cipriano G, Jegou-Penouil MH, Doutre MS. Aggressive intermediate cell histiocytosis successfully treated by 2-chlorodeoxyadenosine. J Eur Acad Dermatol Venereol. 2008 Sep. 22(9):1153-6. [Medline].

  279. McCowage GB, Frush DP, Kurtzberg J. Successful treatment of two children with Langerhans' cell histiocytosis with 2'-deoxycoformycin. J Pediatr Hematol Oncol. 1996 May. 18(2):154-8. [Medline].

  280. Stine KC, Saylors RL, Williams LL, Becton DL. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol. 1997 Oct. 29(4):288-92. [Medline].

  281. Bernard F, Thomas C, Bertrand Y, Munzer M, Landman Parker J, Ouache M. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer. 2005 Nov. 41(17):2682-9. [Medline].

  282. Apollonsky N, Lipton JM. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinosine. J Pediatr Hematol Oncol. 2009. 31(1):53-6.

  283. Allen CE, Flores R, Rauch R, Dauser R, Murray JC, Puccetti D. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010 Mar. 54(3):416-23. [Medline].

  284. McClain KL. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother. 2005 Nov. 6(14):2435-41. [Medline].

  285. Abraham A, Alsultan A, Jeng M, Rodriguez-Galindo C, Campbell PK. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis. Pediatr Blood Cancer. 2013 Jun. 60(6):E19-22. [Medline].

  286. Abella EM, Artrip J, Schultz K, Ravindranath Y. Treatment of familial erythrophagocytic lymphohistiocytosis with cyclosporine A. J Pediatr. 1997 Mar. 130(3):467-70. [Medline].

  287. Jakobson AM, Kreuger A, Hagberg H, Sundström C. Treatment of Langerhans cell histiocytosis with alpha-interferon. Lancet. 1987 Dec 26. 2(8574):1520-1. [Medline].

  288. Bisphonates to the "rescue" of bony lesions and recurrences in Langrhans cell histiocytosis. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina. Oct 2006.

  289. Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001 May. 138(5):728-34. [Medline].

  290. Egeler RM, de Kraker J, Voûte PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol. 1993. 21(4):265-70. [Medline].

  291. Ceci A, de Terlizzi M, Colella R, Loiacono G, Balducci D, Surico G, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X '83 study. Med Pediatr Oncol. 1993. 21(4):259-64. [Medline].

  292. Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol. 1994. 23(2):72-80. [Medline].

  293. Children's National Medical Center. New hope for children with multi-system LCH. May 30, 2013. Available at http://www.histio.org/document.doc?id=720.

  294. Jahraus CD, Russo S, Peñagarícano J, Routh A, St Clair W. Radiotherapy dose fractionation in pediatric Langerhans cell histiocytosis. South Med J. 2004 Dec. 97(12):1268-9. [Medline].

  295. Sedky MS, Rahman HA, Moussa E, Taha H, Raafat T, Hassanein O. Langerhans Cell Histiocytosis (LCH) in Egyptian Children: Does Reactivation Affect the Outcome?. Indian J Pediatr. 2015 Jul 3. [Medline].

  296. Maschan M, Novichkova G, et al. 2-chlordeoxyadenosine and intermediate-dose cytosine arabinoside combinatin therapy for high-risk Langerhans cell histiotytosis (HR-LCH). Presented at: 21st Annual Meeting of the at Histiocyte Society; Vancouver, British Columbia, Canada. September,2005.

  297. Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005 Aug. 153(2):254-73. [Medline].

  298. Mauro E, Fraulini C, Rigolin GM, Galeotti R, Spanedda R, Castoldi G. A case of disseminated Langerhans' cell histiocytosis treated with thalidomide. Eur J Haematol. 2005 Feb. 74(2):172-4. [Medline].

  299. McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan. 48(1):44-9. [Medline].

  300. Brown RE. The NF-kappaB pathway and the successful application of anti-inflammatory and angiostatic therapy in Langerhans' cell histiocytosis. Br J Haematol. 2005 Jul. 130(1):147-8. [Medline].

  301. Putters TF, de Visscher JG, van Veen A, Spijkervet FK. Intralesional infiltration of corticosteroids in the treatment of localised langerhans' cell histiocytosis of the mandible Report of known cases and three new cases. Int J Oral Maxillofac Surg. 2005 Jul. 34(5):571-5. [Medline].

  302. Akkari V, Donadieu J, Piguet C, Bordigoni P, Michel G, Blanche S, et al. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplant. 2003 Jun. 31(12):1097-103. [Medline].

  303. Stéphan JL, Donadieu J, Ledeist F, Blanche S, Griscelli C, Fischer A. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A. Blood. 1993 Oct 15. 82(8):2319-23. [Medline].

  304. Komp DM. Long-term sequelae of histiocytosis X. Am J Pediatr Hematol Oncol. 1981 Summer. 3(2):163-8. [Medline].

  305. Bernstrand C, Sandstedt B, Ahström L, Henter JI. Long-term follow-up of Langerhans cell histiocytosis: 39 years' experience at a single centre. Acta Paediatr. 2005 Aug. 94(8):1073-84. [Medline].

  306. Torkos A, Czigner J, Kiss JG, Tóth F, Szamosközi A, Jóri J. Cochlear implantation for treatment-induced ototoxic deafness in Langerhans cell histiocytosis. A case report. Eur Arch Otorhinolaryngol. 2005 Jun. 262(6):496-500. [Medline].

  307. Gayhed D, van't Hooft I, Laurencikas E. Neuropsychological profiles in children with CNS-LCH. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina. Oct 2006.

  308. Minkov M, Steiner M, Arico M. Risk organ involvement at reactivation of Langerhans cell histiocytosis (LCH): frequency, course, and outcome. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina. Oct 2006.

  309. Cooksley N, Judge DJ, Brown J. Primary pulmonary Hodgkin's lymphoma and a review of the literature since 2006. BMJ Case Rep. 2014 Apr 7. 2014:[Medline].

  310. Feldman J, Callebant I, Roposo G. MUNC 13-4 is essential for cytotoxic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003. 115(4):461-73.

  311. Perry MC, Harrison EG Jr, Burgert EO Jr, Gilchrist GS. Familial erythrophagocytic lymphohistocytosis. Report of two cases and clinicopathologic review. Cancer. 1976 Jul. 38(1):209-18. [Medline].

  312. Rodriguez-Galindo C, Jeng M, Khuu P, McCarville MB, Jeha S. Clofarabine in refractory Langerhans cell histiocytosis. Pediatr Blood Cancer. 2008 Nov. 51(5):703-6. [Medline].

 
Previous
Next
 
Erosion of the gingiva that creates the appearance of premature eruption of the teeth in a young child.
Clinically detectable skull lesions in a child with advanced Langerhans cell histiocytosis (LCH).
Cutaneous Langerhans cell histiocytosis (LCH) in a child. Skin infiltrates are seen on the face, and the chest has maculoerythematous, petechial, and xanthomatous appearance.
Severe scalp disease in a patient with scaly erythematous patches. Patches of alopecia are present. The lesions were not pruritic.
Photomicrograph shows sample of Langerhans cell histiocytosis (LCH) that immunocytochemically stains positive for S-100 protein.
Photomicrograph of Langerhans cell histiocytosis (LCH) stained with hematoxylin and eosin. The characteristic Langerhans cells have reniform or convoluted nuclei and abundant cytoplasm.
Transmission electron micrograph shows a diagnostic rod-shaped Langerhans Birbeck granule.
Transmission electron photomicrograph shows Langerhans cells characterized by convoluted nuclear contours and abundant cytoplasm.
Radiograph of lytic lesions of the skull reveals a punched-out pattern without evidence of periosteal reaction or marginal sclerosis.
Three-dimensional reconstructive view of skull lesions in a child with Langerhans cell histiocytosis.
Genetic defect/syndrome Genetic Defect Protein Frequency % FHL cases (location) Mutation Type Function
FHLH1 Unknown (9 gr 21.3-22) Rare



Pakistan



FHLH2 PRF



(10 gr 21-22)



Perforin 20-40%



Often in blacks, Turks, Japanese



>50 deletions, non-sense and missense mutations; heterozygosity for C272T, A91V substitution Pore-forming protein
FHLH3 UNC13D



(17 gr 25)



MUNC 13-4 20-30%



Worldwide, Turks, Kurds, US, Europe



>18 deep intronic mutations and large inversion Vesicle forming
FHLH4 STX 11



(6 gr 24)



Syntaxin-11 10-20%



Worldwide, Central Europe, Turkey, Saudi Arabia



Variable Vesicle transport and fusion
FHLH5 STXBP2



(19p)



MUNC 18-2 5-20%



Worldwide ,Italy, UK, Kuwait, Pakistan, North America



Multiple motatronin MUNC 18-2, impaired binding to syntaxin-11 Vesicle transport and fusion SNARE complex assembly and disassembly
Immune deficiency and albinism
Chédiak-Higashi syndrome LYST LYST Rare



Worldwide



Size function of lytic granules
Griscelli syndrome type II Rab 27A Rab 27A Rare



Northern Europe



Vesicle docking, granule movement
Hermansky-Pudlak syndrome Type II AP3B1 Rare



Worldwide



Vesicle biogenesis, protein sorting
Primary Immune Deficiencies
X-linked lymphoproliferative disease Type I SH2D1A SAP Worldwide Signal transduction, activation of lymphocytes
X-linked lymphoproliferative disease Type II BIRC4 XIAP Worldwide Inhibition of apoptosis
ITK deficiency ITK ITK Worldwide T-cell kinase
Table 2. Laboratory and Imaging Studies in Patients With LCH
Type of Study Study Involvement With Monostotic Lesion
Laboratory Hemoglobin and/or hematocrit Monthly Every 6 mo None
Leukocyte count and differential cell count Monthly Every 6 mo None
Liver function tests* Monthly Every 6 mo None
Coagulation studies Monthly Every 6 mo None
Urine osmolality test after overnight water fast Every 6 mo Every 6 mo None
Radiography Chest, posteroanterior and lateral Monthly Every 6 mo None
Skeletal survey Every 6 mo None Once at 6 mo
* Measurements of alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase.
Table 3. Indication for Laboratory Evaluations Based on Findings in LCH
Evaluation Indication Follow-Up Interval
Bone-marrow aspiration biopsy Anemia, leukopenia, or thrombocytopenia 6 mo
Pulmonary function tests Abnormal chest radiographic findings, tachypnea, intercostal retractions 6 mo
Lung biopsy after bronchoalveolar lavage, if available* Abnormal findings on pretreatment chest radiography to rule out infection None
Small-bowel series and biopsy Unexplained chronic diarrhea, failure to thrive, malabsorption None
Hepatic ERCP, angiography, or biopsy High liver enzyme levels and hypoproteinemia not caused by protein-losing enteropathy to rule out active LCH vs liver cirrhosis When all evidence of disease resolves but hepatic dysfunction persists
IV gadolinium-enhanced MRI of brain and hypothalamic-pituitary Visual, neurologic, hormonal abnormalities 6 mo
Panoramic radiography of the teeth, mandible, and maxilla; consultation with an oral surgeon Oral involvement 6 mo
PET scan Surveillance 6 mo
Endocrine investigation Growth failure, diabetes insipidus, hypothalamic syndromes, galactorrhea, precocious or delayed puberty; hypothalamic and/or pituitary abnormality on CT or MRI None
Consultation with an audiologist and an otolaryngologist Aural discharge, impaired hearing 6 mo
Note.—ERCP = endoscopic retrograde cholangiopancreatography; IV = intravenous.



* Diagnostic findings on bronchoalveolar lavage obviate lung biopsy.



Table 4. Cell Markers and Phenotypes of Histiocytic and Related Disorders
Cell Marker LCH SHML Follicular Dendritic Tumor Histiocytic Sarcoma Acute Monocytic Leukemia Anaplastic Large-Cell Lymphoma
CD1a + - - - - -
CD4 + + - + + +
CD21 - +/- + - - -
CD25 - + - + + ++
CD30 - - - - - ++
CD35 - + + - - -
CD45 - + - +/- + +/-
CD68 - + - + + +/-
ALK-1 - - - - - +
S-100 + + - +/1 - -
Lysozyme - + - + + -
Table 5. Stains for Diagnosing Histiocytosis
Type of Test Stain Mononuclear Phagocytic System Langerhans Cells Interdigitating Dendritic Cells Dendritic Reticulum Cells
Frozen-section enzyme histochemistry Nonspecific esterase - - - -
Acid phosphatase + - - -
ATPase - + + -
Lambda-mannosidase - + - -
5' nucleotidase - - - +
Immunohistochemistry CD14 (Leu M3/MY4) + + + +
CD11 C (Leu M5) + + + +
CD68 (EBM 11) + - - -
CD1a - + + -
Paraffin-section immunohistochemistry HLA-DR + + + +
CD68 + - - -
Mac 387 + - - -
Lysozyme + - - -
Alpha-antitrypsin + - - -
S-100 - + + -
Peanut agglutinin Diffuse Halo and dot Halo and dot -
Note.—ATPase = adenosine triphosphatase; HLA = human leukocyte antigen.
Table 6. Labeling Pattern of Histiocytes and Dendritic Cells
Marker Histiocytes Langerhans Cells Interdigitating Cells Follicular Dendritic Cells
CD1a 0 S 0 0
S-100 protein 0 S S W
HLA-DR S S S W
CD45 S W W 0
Alpha-naphthyl acetate esterase S W W W
ATPase W S S S
Fascin 0 0 S S
R4/23 0 0 0 S
Note.—0 = no staining; S = strong and constant; W = weak or inconstant.
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.